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Bone marrow (BM)-derived endothelial progenitor cells (EPCs) have a critical role in tumor 
vasculogenesis, mobilizing to tumors and supporting de novo formation of blood vessels 
essential for tumor growth and metastasis.  Vascular endothelial growth inhibitor (VEGI; TL1A) 
is a member of the tumor necrosis superfamily (TNFSF15) and is produced predominantly by 
endothelial cells (ECs).  VEGI has been shown to act in an autocrine manner by specifically 
targeting ECs to inhibit their proliferation and induce apoptosis, resulting in elimination of ECs 
in established tumor vasculature and inhibition of angiogenesis.  However, it remains unclear 
whether VEGI exerts its function solely on fully differentiated ECs or if it is able to modulate 
BM-derived EPCs as well.  Here, the effect of recombinant VEGI on BM-derived EPC function 
is evaluated in an effort to establish the potential therapeutic value of VEGI.  We found that 
VEGI inhibits the differentiation of EPCs from murine BM under EC stimulating culture 
conditions.  Consistently, VEGI treatment decreases the capability of the cells to adhere, migrate 
and form capillary-like structures necessary for vascular formation.   Additionally, differentiated 
BM-derived EPCs in cultures underwent apoptosis in response to VEGI treatment.  To 
investigate the impact of VEGI on BM-derived EPC-supported tumor vasculogenesis, mice 
bearing Lewis lung carcinoma (LLC) tumors were treated with intraperitoneal injection of 
recombinant VEGI.  VEGI treatment significantly decreased the population of BM-derived EPCs 
found in the tumors while increasing their population in the bone marrow. Furthermore, an 
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overall increase in apoptosis of BM-derived cells at the tumor site was observed after VEGI 
treatment.  Our results indicate VEGI prevents incorporation of BM-derived EPCs into LLC 
tumors, resulting in the inhibition of EPC-supported tumor vasculogenesis and tumor growth.  
Together, these findings suggest that VEGI takes part in the modulation of tumor vasculogenesis 
by inhibiting BM-derived EPC differentiation and mobilization as well as inducing apoptosis.  
These studies yield important insights into the function of VEGI in postnatal vasculogenesis, 
helping to facilitate the development of therapeutic uses of VEGI in cancer. 
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1.0  INTRODUCTION 
Anti-angiogenesis is an important avenue and approach to cancer therapy.  The development of 
anti-angiogenic drugs has focused on endogenous angiogenesis inhibitors that innately modulate 
endothelial cell (EC) growth.  Increasing evidence points to tumor vasculogenesis as a principle 
mechanism for the support and growth of tumors.  Therefore, the discovery of endogenous 
inhibitors which are able to not only suppress tumor angiogenesis, but tumor vasculogenesis as 
well, is of high therapeutic value. 
 
1.1 NEOVASCULARIZATION 
1.1.1 Angiogenesis 
The vascular endothelium is an essential component of the cardiovascular system and provides a 
dynamic barrier between circulating blood and surrounding tissues in the body.  The endothelium 
monolayer plays a vital role in regulating vascular homeostasis, coagulation and inflammation, 
and as such, restoration of the monolayer is essential following damage or cell death [1, 2].  
Under normal conditions, the endothelium undergoes a low turnover rate, retaining ECs in a 
quiescent state in order to maintain vascular homeostasis [3].  However, the number of 
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circulating ECs found in a healthy subject can be stimulated to proliferate during postnatal 
neovascularization, such that occurs following acute stress or injury of the vascular endothelium.   
It has been commonly believed that postnatal neovascularization, the vascular growth and 
remodeling in newborns and adults, is mainly attributed to angiogenesis, a process of capillary 
sprouting from pre-existing capillary vessels (Figure 1) [4].  The process of angiogenesis can 
occur during normal physiological conditions such as embryonic development and the female 
reproductive cycle.  Angiogenesis can also be engaged under pathological conditions such as 
tumor growth, macular degeneration, ischemia and rheumatoid arthritis [1, 5]. 
The angiogenic response is a complex process that has been well studied and it involves 
extensive cellular adhesive interactions between ECs and surrounding extracellular matrix 
components.  The initial step in angiogenesis begins with vasodilation and increased 
permeability of pre-existing capillaries.  Next, pericytes surrounding the capillaries detach and 
the EC basement membrane is degraded by proteases.  This allows for the migration of ECs into 
the interstitial space for sprouting.  During migration, ECs interact with the extracellular matrix 
via interactions with cell surface integrin such as αvβ3 and αvβ5.  ECs then undergo proliferation 
and elongation at the migrating tip and adhere to begin lumen formation. The newly formed 
vessel then generates a new basement membrane by recruiting pericytes to stabilize the vessel 
wall, leading to formation of intact microvessels and blood flow [6, 7].   
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Figure 1.  Schematic representation of angiogenesis and vasculogenesis. 
Vasculogenesis is the aggregation of EPCs, which migrate from distant sites, to form blood vessels.  
Angiogenesis is the formation of new vessels via sprouting from pre-existing vessels.  Both processes can 
occur simultaneously during formation of a new vasculature. Figure taken from [8]. 
1.1.2 Vasculogenesis 
The proliferation, migration, and stabilization of blood vessels formed during neovascularization 
is necessary for repairing injured tissues or meeting increased metabolic demands [9].  Until a 
decade ago, it was thought that postnatal neovascularization occurred primarily via angiogenesis.  
However, the capacity of mature ECs to create new vessels is limited since they are terminally 
differentiated cells with a low proliferative potential.  The discovery of progenitor cells of 
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endothelial lineage in the circulation of adults that can differentiate into mature ECs has 
suggested an alternate paradigm for neovascularization [10, 11].  A growing body of data 
demonstrates that these endothelial progenitor cells (EPCs) contribute to postnatal 
neovascularization by participating in vasculogenesis, the de novo formation of new blood 
vessels, a process originally thought to occur only during embryogenesis (Figure 1) [1, 12].  
During embryonic development, the process of vasculogenesis involves the growth and 
fusion of multiple blood islands that eventually result in the formation of a capillary network 
within a previously avascular yolk sac [13].  This capillary network differentiates into an 
arteriovenous vascular system after blood circulation begins [14].  The embryonic blood islands 
are composed of cells destined to become either the blood cells that circulate in the vascular 
system or the ECs responsible for the construction of blood vessels.  The center of the embryonic 
blood island consists of hematopoietic stem cells (HSCs) which are destined to generate 
hematopoietic blood cells.  Situated on the periphery of the blood islands are EPCs [15].  HSCs 
and EPCs not only have a spacial association, but they are also considered to be derived from a 
common precursor, known as a hemangioblast [12, 16].    
In recent years, accumulating evidence points to EPCs playing a critical role in 
vasculogenesis, which is essential for normal physiological neovascularization during tissue 
growth, wound healing, and organ regeneration [17, 18].  Postnatal vasculogenesis also 
contributes to endogenous neovascularization of developing tumors, severe hindlimb ischemia, 
and myocardial ischemia [18].   In the adult, EPCs are believed to be recruited from the bone 
marrow, migrate to sites requiring neovascularization, and participate in the assembly of newly-
forming blood vessels [11, 19].  
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1.1.3 Tumor Neovascularization 
The development of a single cancerous cell into a malignant tumor mass is a multistep process 
[20].  Malignant transformation of tumor cells requires the generation of a fertile 
microenvironment in which tumor cells can proliferate and interact with a complex network of 
stromal cells and neovessels (Figure 2). During the premalignant stages of carcinogenesis, tumor 
cells manifest altered responses to factors in the extracellular microenvironment, resulting in 
uncontrolled cell proliferation.  There have been numerous reports that indicate the growth of 
tumors depends on the rapid recruitment of ECs to contribute to a functional neovasculature.  
Vascular formation within a tumor also allows for the distribution of cancerous cells to 
secondary sites [21].   
Unlike a normal vasculature, the vasculature of a tumor is dilated [22], leaky [23], and 
disorganized [24].  These characteristics cause tumor vasculatures to lack stability and can 
occasionally lead to micro-hemorrhages or vessel collapse [25].   The development of blood 
vessels within a tumor occurs in response to the demand for nutrients and oxygen by the growing 
tumor mass.  There is a physical limit, about 100 µm, to the distance small molecules are able to 
diffuse across the stroma between a nearby capillary and the tumor mass [21, 26].  Once that 
limit is surpassed, hypoxic conditions occur in the center of the tumor, inducing angiogenesis via 
a step termed the “angiogenic switch,” in which the balance between activators and inhibitors of 
angiogenesis tips in favor of pro-angiogenesis [26, 27]. 
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Figure 2.  The progression of a tumor to a malignant phenotype. 
Genetic abnormalities lead to the growth of a small microscopic tumor to a highly vascularized tumor 
mass.  Tumor progression is marked by the ability of the tumor to secrete pro-angiogenic growth factors 
that induce an angiogenic state, resulting in the recruitment and formation of new of blood vessels from 
the surrounding stroma, which allows for the growth of a macroscopic tumor. The new vasculature then 
permits metastasis, leading to the eventual death of the host.  Figure modified from [6]. 
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Early theories of tumor neovascularization revolved solely around angiogenesis being the 
source of a tumor’s vascular supply [4, 22].  It was suggested that vessels can be either co-opted 
from adjacent remodeled pre-existing capillaries or that ECs from surrounding established 
vessels can proliferate and migrate to cause capillary sprouting [22, 27-29].  However, abnormal 
neovascularization under disease conditions, such as that in cancer development, also involves 
postnatal vasculogenesis [4, 18, 30].  Recent evidence shows that EPCs migrate from the bone 
marrow to the tumor site and differentiate into a new endothelium in the tumor bed, providing an 
alternative method of tumor vascularization [31].  
EPCs play an important role in tumor growth by contributing to tumor neovasculature, as 
shown with increased EPC markers in the tumors of cancer patients [30, 32, 33]. It has been 
shown that EPCs control the angiogenesis switch, a critical step in the transition of an avascular, 
dormant tumor to a vascularized, rapidly growing tumor [34]. It has also been shown that EPCs 
are subject to stimulation by vascular endothelial growth factor (VEGF), and that targeting 
VEGF or modifying the bone marrow to express an angiogenesis inhibitor blocks tumor growth 
[35]. 
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1.2 ENDOTHELIAL PROGENITOR CELLS 
1.2.1 Discovery 
EPCs are defined as cells that are capable of differentiating into ECs by showing characteristics 
of stemness (proliferative capacity and resistance to stress) and clonal expression (the ability of a 
single cell to multiply) [36].  Prior to 1997, EPCs were thought to exist only in embryos and 
were initially known as angioblasts.  These cells were derived from extra-embryonic 
mesenchyme cells and differentiated into mature ECs to aid in the formation of primitive blood 
vessels [37].   However in 1997, Asahara et al. reported the first detailed description of the 
isolation of adult bone marrow (BM)-derived EPCs from human peripheral blood [11].  Since 
then, there has been a vast amount of research interest in EPCs.  
 Research on avian embryonic development has suggested that embryonic EPCs and 
hematopoietic cells are derived from one common precursor cell, putatively termed the 
hemangioblast [15].  The hemangioblast originates from the mesoderm germ layer of epiblasts 
and symmetrically divides to form angioblasts and pluripotent HSCs [37].  Available 
accumulating evidence points to the existence of hemangioblasts in adults [37, 38].  The 
identification of HSCs in peripheral blood and bone marrow that could sustain hematopoietic 
reconstitution provided evidence for HSCs in adult tissues [39, 40].  Their related descendants, 
EPCs, have been isolated along with HSCs in hematopoietic organs [15].  The existence of adult 
hemangioblasts strongly suggests EPCs contribute to the maintenance and repair of the vascular 
and hematopoietic systems.  Moreover, adult hemangioblasts will aid in the development of new 
therapies in the treatment of disease, and to the further understanding of EPCs. 
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1.2.2 Location 
EPCs can be found in bone marrow, peripheral blood and umbilical cord blood.  It is proposed 
that EPCs originate from the Lin--c-Kit+-Sca-1+ population of mouse bone marrow and it has 
been shown that Sca-1+ cells can function as EPCs [41].  Similar to the peripheral blood in 
adults, umbilical cord blood is also a rich source of EPCs and contains high levels of CD133+ 
and CD34+ HSCs that can differentiate into ECs ex vivo [42, 43].  Additionally, it has been 
demonstrated that the human embryonic aorta contains EPCs capable of differentiating into 
mature ECs under culture conditions [44].   
More recently, EPCs have also been identified within the walls of adult blood vessels.   
Human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) 
derived from vessel walls are normally considered to be fully mature ECs. However, it was 
shown that HUVECs and HAECs could be passaged for at least 40 population doublings, 
indicating a hierarchy of EPCs within HUVEC and HAEC monolayers that can be discriminated 
by their clonogenic potential [42].  In line with these data, the existence of EPCs in a distinct 
zone of the vascular wall between the smooth muscle and connective tissue layers was found.  
Moreover, it was demonstrated that EPCs exist in the wall of adult human blood vessels of 
several organs, among them the liver [45]. 
Other studies have shown that EPCs can be derived from myeloid cells.  These cells are 
located inside the peripheral blood and they have the ability to cross-differentiate into the EC 
lineage. Current studies have suggested that these monocyte-derived EPCs are less able to 
proliferate compared to EPCs derived from cord blood or the adult bone marrow, however they 
still have a comparable ability to contribute to neovascularization.  It is thought 
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that either the proliferation capacity of EPCs is not important in vivo, or that these monocyte-
derived EPCs produce growth factors that help balance their inability to undergo ample 
proliferation [36, 46]. 
1.2.3 Isolation and Characterization 
EPCs were initially identified by the co-expression of CD34 (an antigen expressed by all HSCs 
that is lost as it differentiates) and Flk-1 (VEGFR2, a receptor for vascular endothelial growth 
factor) on the surface of these cells [11].  Asahara et al. used a polyclonal antibody to show that 
CD34+ and Flk-1+ isolated cells can differentiate into ECs in vitro. When CD34+, Flk-1+, CD34−, 
or Flk-1− cells were injected into mice, rats and rabbits undergoing neovascularization due to 
hindlimb ischemia, CD34+ and Flk-1+ cells, but rarely CD34− or Flk-1− cells, incorporate into the 
vasculature in a manner consistent with vasculogenesis, a paradigm otherwise restricted to 
embryogenesis.   After administration to mice, EPCs were shown to differentiate in vivo into ECs 
that associate with vessels and express PECAM-1 (CD31, an EC marker).  Intravenous 
administration of mature ECs failed to result in incorporation of these cells into the foci of 
neovascularization [11].  In this manner, BM-derived EPCs were shown to be functionally 
distinct from mature ECs. 
EPCs can be isolated using magnetic micro beads, adherence culture and flow cytometry. 
Once isolated, the cells are cultured on fibronectin coated plates containing medium with specific 
growth factors, such as VEGF and epidermal growth factors, to facilitate the growth of 
endothelial-like cells.  After initial adhesion in vitro, EPCs begin to lose their progenitor 
characteristics and start to differentiate [11, 47-50].  Since the initial isolation of EPCs, a number 
of groups have set out to better define this cell population by identifying their expression pattern 
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of cell surface markers [19, 47, 49, 51].  EPCs were shown to express combinations of surface 
markers including Flk-1, E-selectin, fibroblast growth factor (FGF) receptor, CD34, c-Kit, 
CD31, von Willebrand factor (vWF), vascular endothelial cadherin (VE-cadherin), Tie-2 
(angiopoietin-1 receptor precursor), and CD133 (AC133; prominin-1) [48, 52]. However, to date 
there is neither an exclusive EPC marker nor a simple definition of EPC characteristics.  EPCs 
may therefore encompass a group of cells existing in a variety of stages ranging from primitive 
hemangioblasts to fully differentiated ECs. 
EPCs can be roughly subdivided into three inter-related classes. One class of EPCs is 
represented by cells that are likely to be hemangioblasts. In mice, this includes Lin−-c-Kit+-Sca-
1+ cells and Sca-1+-c-kit+-CD34− cells from the bone marrow [53, 54].  In humans, this includes 
CD113+, CD34+, and Flk-1+ cells from the bone marrow and blood [11, 49]. Two subpopulation 
classes of EPCs with distinct patterns of cell growth and ability to secrete angiogenic factors 
have been described.  The two populations are termed early and late EPCs.  Early and late EPC 
populations differ in their morphology.  Early EPCs are spindle-shaped cells that have a peak 
growth in culture at 2–3 weeks and die around week 4 [46].  Late EPCs are cobblestone shaped 
and usually appear after 2–3 weeks in culture and can be maintained for up to 12 weeks [46, 55].  
Although their putative precursors and the exact differentiation lineage of EPCs remain to be 
determined, it is believed that early EPCs which are localized in the bone marrow or found 
immediately after migration into the circulation are CD133+-CD34+-Flk-1+ cells, whereas later 
stage circulating EPCs are still positive for CD34+-Flk-1+ but lose CD133 and begin to express 
other cell surface markers typical to mature ECs [31]. 
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Another method of EPC evaluation is to determine their ability to support vasculogenesis.  
Evaluation of the angiogenic properties of EPCs utilizes assays that test the migration and tube 
formation capabilities of the cells to generate capillary-like EC networks.  The migration assay is 
based on the chemotactic ability of EPCs.  Cultured EPCs are harvested, counted, resuspended in 
fresh medium, and then moved to a modified Boyden chamber placed in a culture dish 
containing VEGF.  The EPCs will migrate to the lower side of the filter toward the stimulating 
factor.  The filter can then be washed and EPCs that have migrated can be counted [56].  To 
analyze tube formation, an assay is used in which EPCs obtained after culture are placed on a 
basement membrane matrix gel (Matrigel).  After additional days of culture on the Matrigel, the 
number of EC networks, designated as tubes, can be detected and counted [57].   
Although surface markers are the primary indicator of EPCs, they can be downregulated, 
making a sole antigen unreliable as the definitive marker of adult EPCs [58].  For example, EPCs 
found in the peripheral blood are positive for CD133, but can also be negative for CD133, a 
benchmark indicator for EPCs maturing into ECs [59].  CD133, a five transmembrane 
glycoprotein whose function is unknown, is a novel HSC marker and its expression is rapidly 
downregulated as hematopoietic progenitors and EPCs differentiate [60].  However, in 
conjunction with other protein markers, it is possible to depict a cell that is likely an EPC.  It was 
demonstrated that a subset of CD133+ cells mobilized from the peripheral blood can differentiate 
into EC when cultured in the presence of VEGF, fibroblast growth factor-2 (FGF-2), and 
collagen.  Maturation and in vitro differentiation of these cells abolished CD133 expression [49].  
Phenotypic analysis revealed that most of these cells displayed endothelial features, including the 
expression of Flk-1, Tie-2, and vWF [61-64]. All these data indicate that CD133 is a major 
candidate as the selective marker for identifying early EPCs with angioblast potential.  Cells that 
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are CD34+, Flk-1+, and CD133+ constitute a phenotypically and functionally distinct population 
of EPCs that may play a role in postnatal vasculogenesis.  However, because CD133 is expressed 
by HSCs as well [65], the method for differentiating between immature EPCs, committed 
hematopoietic cells, and their putative common precursor, the hemangioblast, has yet to be 
developed further.  Identification of their differences is further complicated by the fact that 
hematopoietic cell subsets express markers similar to those of ECs [33, 66]. 
1.2.4 Mobilization 
To support vascularization, EPCs must mobilize to the site of neovascularization and 
differentiate into mature ECs.  Within the bone marrow, EPCs are in a quiescent state.  When the 
body is developing new blood vessels (such as during the developmental stage), or affected by 
injury, EPCs are activated and migrate into the vascular zone of the bone marrow where 
proliferation is increased.  Various injuries such as ischemia, atherosclerotic lesions, traumatic 
wound, tumor angiogenesis [67-70], and heart infarction [71] cause the frequency of EPCs in the 
peripheral blood to increase up to 50-fold [68].  Although the molecular pathways involved in 
EPC mobilization are in the early stage of definition, the up-regulation of VEGF is thought to be 
a significant contributor to this mechanism [72].  VEGF is thought to be a key cytokine that 
effectively induces the mobilization of EPCs and HSCs into the circulation by interaction with its 
receptors (VEGFR-2 and VEGFR-1) [73].   
VEGF can activate matrix metalloproteinase-9 (MMP-9) on EPCs.  MMP-9 cleaves the 
membrane-bound kit ligand, a stem cell cytokine, in bone marrow stromal cells to release soluble 
kit ligand, enabling c-Kit+ EPCs to migrate from a quiescent bone marrow niche toward the 
vascular region of the bone marrow, called the vascular zone. This translocation activates EPCs 
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from a quiescent to a proliferative state [74].  Besides activating MMP-9, VEGF also up-
regulates stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR-4 [75, 76].  SDF-1 is 
chemotactic for EPCs and recruits EPCs to sites of neovascularization (Figure 3) [77].  In animal 
studies, local injection of SDF-1 into target organs increases EPC homing to the organ site, but 
only in the presence of VEGF.  In the absence of VEGF, SDF-1 fails to enhance BM-derived cell 
recruitment.  Blocking CXCR-4 abolished progenitor homing, regardless of the presence or 
absence of VEGF.  Therefore, it appears that SDF-1 by itself is not sufficient enough to mobilize 
EPCs without an additional signal, such as VEGF [78].  Because additional studies have 
demonstrated that SDF-1 is essential for the adhesion of BM-derived cells, SDF-1 may 
significantly help to sequester EPCs at the site of vessel formation [76].  These studies indicate 
that VEGF, through interaction with MMP-9 and SDF-1, rapidly triggers the release of EPCs 
into the bloodstream.  Accordingly, VEGF induces the mobilization of EPCs from the bone 
marrow of cancer patients [79, 80] and EPC levels in the circulation rise within 24 hours 
following VEGF treatment [81]. 
Cytokines that induce release of leukocytes or erythrocytes may also influence EPC 
mobilization. Increased numbers of EPCs were reported in animals following exogenous 
granulocyte macrophage colony stimulating factor (GM-CSF) treatment, and accelerated blood 
vessel growth was observed [82]. In another report, granulocyte colony-stimulating factor (G-
CSF) increased incorporation of BM-derived cells into new tumor blood vessels, which 
markedly promoted growth of colon cancer cells that were inoculated subcutaneously in mice 
[83].  Furthermore, levels of erythropoietin (EPO) were found to be significantly associated with 
the number and function of EPCs [84]. Similarly, administration of recombinant human EPO 
increased the number of functionally active EPCs in peripheral blood [85]. 
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Figure 3.  EPCs are involved in blood vessel repair and tumor angiogenesis. 
Increases in the expressions of matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor 
(VEGF), and stromal-derived factor-1 (SDF-1) are responsible for the mobilization of EPCs from the 
bone marrow (BM) into the blood vessels. Figure adapted from [58]. 
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Other molecules that have been shown to facilitate EPC mobilization from the bone 
marrow to the periphery are: Tie 2, FGF, hydroxymethylglutaryl–coenzyme A synthase inhibitor 
[86], 17ß-Estradiol together with FGF-2 [87], and reactive oxygen species (ROS) such as 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) and Rac1 [88].  In 
addition to the above factors, there is also data indicating that placental growth factor [89], 
platelet-derived growth factor-CC [90], nitric oxide [91], physical training [92], and estrogens 
[93] stimulate EPC mobilization as well. Additionally, EPCs express protease cathepsin L [94], 
plasminogen activators, heparinases, chymases, and tryptases [95-97].  These types of proteases 
are important for matrix degradation and invasion by EPCs. 
After EPCs are activated and begin to migrate, a guidance mechanism is required to help 
direct their interaction with the extracellular matrix at the site of vasculogenesis.  One study 
shows that ephB2 and ephB4 enhances SDF-1/CXCR4's signaling and chemotaxis, which 
orchestrates the movement of EPCs to the specific site [98].  A key signaling molecule, Akt, is 
thought to regulate EPC homing and migration by modulating the expression of adhesion 
molecules [99].  When the EPCs interact with the extracellular matrix, they do so by interaction 
with integrins present on the extracellular matrix, such as αvβ3 and αvβ5 [100].  In contrast to 
enhancing EPC migration, there are also additional soluble factors that may inhibit EPC 
vasculogenesis.   C-reactive protein (CRP), which has been shown to be an indicator of vascular 
death, and tumor necrosis factor-α (TNF- α) promote apoptosis, attenuate the function, and 
reduce the number of EPCs [101, 102].  The presence of CRP has yielded decreases in the 
angiogenic potential of EPCs and up-regulates EPC apoptosis by negatively affecting VEGF 
expression. 
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1.3 ROLE OF EPC IN TUMOR VASCULOGENESIS 
Tumors require blood and nutrients in order to grow, proliferate, and metastasize.  Research has 
demonstrated that BM-derived EPCs participate in neovascularization and contribute to tumor 
vascularization [18, 81].  Tumors release various cytokines and chemokines, most notably 
VEGF, angiopoeitin [103], G-CSF[83], and SDF-1 [104].  Because EPCs have receptors for 
these factors, including Flk-1 for VEGF and CXCR-4 for SDF-1, EPCs will hone to the tumor 
site to initiate blood vessel formation.  Once they arrive at the site, EPCs will not only 
differentiate and form cellular clusters to begin developing a functional microvasculature, they 
will also attract more EPCs to the site by causing the tumor to release more VEGF [105, 106].  
Hence, the vicious cycle of tumor growth, proliferation, and metastasis continues. 
The study of tumor neovascularization has focused primarily on the process of 
angiogenesis but has begun to shift with the growing body of data that suggests vasculogenesis is 
an important mechanism for activating the angiogenic switch [34].  The availability of transgenic 
mice where β-galactosidase (Lac-Z) or green fluorescent protein (GFP) are expressed in ECs or 
in all tissues has helped with the understading of EPC-supported tumor vasculogenesis.  Asahara 
et al. subcutaneously injected murine colon cancer cells into mice engrafted with bone marrow of 
transgenic mice constitutively expressing Lac-Z from EC-specific promoters. Three weeks after 
tumor implantation, histological examination of the tumors showed multiple Lac-Z+ cells at sites 
of tumor xenotransplants, both within the tumor stroma and incorporated into the endothelial 
layer of tumor blood vessels [11]. 
Lyden et al. further studied the role of BM-derived EPCs in tumor growth using inhibitor 
of differentiation (Id)-mutant mice that were unable to support growth of implanted tumors 
because of defects in angiogenesis [33].   BM transplantation from wild-type mice, not from Id-
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mutant mice, restored the tumor neovascularization and growth in Id-mutant mice.  Examination 
of the tumors revealed that BM-derived EPCs contributed to more than 90% of the endothelium, 
suggesting that vasculogenesis played an overwhelming role in tumor neovascularization [33].  
In subsequent animal transplantation models, EPCs were incorporated into neovessels, 
sometimes by as much as 50% [107], whereas other authors reported lower but significant levels 
between 10% and 20% [108].  
Gao et al. examined whether BM-derived EPCs directly contribute to vasculogenesis and 
progression of micrometastisis to macrometastasis in vivo [34].  To facilitate identification of 
tumor cells and BM-derived EPCs, the authors inoculated GFP+ chimeric mice with Lewis lung 
carcinoma (LLC) cells expressing red fluorescent protein.  They observed that during tumor 
growth, there was a window during which tumor cells undergo an angiogenic switch and 
significant vessel infiltration can then be seen.  Nearly 13% of the ECs in the tumor vessels 
expressed GFP and CD31.  In addition, blocking EPC mobilization causes severe angiogenesis 
inhibition and significantly impairs tumor progression, leading the authors to determine that 
EPCs are critical regulators of the angiogenic switch [34]. 
Other studies have investigated the role of vasculogenesis in human tumors by assessing 
patients who developed malignancies after bone marrow transplantation from donors of the 
opposite sex.  By colocalizing sex chromosome–specific probes with ECs markers, it was found 
that the percentage of BM-derived ECs in the tumor vasculatures ranged from 1% (head and 
neck sarcoma) to 12% (lymphoma), with a mean of 4.8% [109].  Furthermore, EPCs have been 
detected at increased frequency in the peripheral blood of patients with various malignancies 
including lung [110], hepatocellular [80], breast [78], and colorectal [111] cancers, as well as 
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myeloma multiplex [112], myelofibrosis [113], non-Hodgkin's lymphoma [114], acute myeloid 
leukemia [115], and malignant gliomas [116].  
These observations have been challenged by some studies in which EPCs had no 
measurable contribution to tumor neovessels.  In a bone marrow transplantation model in which 
donor bone marrow was transduced with a lentiviral vector encoding GFP driven by the 
endothelial-specific Tie-2 promoter, it was estimated that only 0.05% of blood vessels in tumor 
xenografts were derived from BM-derived EPCs [107].  Similar reports were shown in 
transplantation models using bone marrow cells with GFP ubiquitously expressed, suggesting no 
contribution of BM-derived EPCs to the endothelial lining of tumor vessels.  These results 
conflict with multiple prior reports on EPC contribution to tumor vasculogenesis and may be due 
to differences in methodology.  It appears the contribution of BM-derived EPCs to tumor 
vasculature depends heavily on the experimental model. 
Efforts to quantify tumor reliance on vasculogenesis have suggested a wide variation in 
EPC-supported vasculogenesis in mouse models, ranging from 0% to more than 90% [33, 117, 
118]. The wide variation in the degree of tumor vasculogenesis may be the result of different 
surface markers used for detection, different model systems (e.g., different reporter constructs 
and types of tumor) or the method of tissue sampling (e.g., vasculogenic vessels were not 
uniformly distributed but occurred in “hotspots”) [118-120].  Data suggest that BM-derived EPC 
involvement in tumor vascularization might also vary depending on the tumor stage [121, 122].  
In one study, it was shown that only advanced tumors incorporate BM-derived EPCs into 
neovessels, perhaps in response to the increasing demand for a larger blood supply by the tumor 
[122].  Another study by Nolan et al. suggests BM-derived EPCs are incorporated at a high 
efficiency (20-30%) into the vasculature for a brief period during the early phase of tumor 
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growth (days 4-6 following tumor implantations).  In the weeks following, BM-derived EPC 
becomes diluted by local non-BM-derived EPCs, resulting in only 1% of EPCS to be detected in 
the tumor after 4 weeks of growth [123].   
Future studies to examine location and numbers of BM-derived cells during tumor 
progression are necessary to further our understanding of their importance in tumor 
vasculogenesis. Although angiogenesis is overwhelmingly the most widely studied process, it is 
not the only mechanism of blood vessel formation within a tumor.  Tumor vascularization may 
be supported by the mobilization and functional incorporation of BM-derived EPCs. As such, 
EPCs have been detected at increased frequency in the circulation of cancer patients and 
lymphoma bearing mice [124, 125].  Additionally, tumor volume and tumor secretion of VEGF 
were found to be correlated with EPC mobilization [124, 125]. Because vascularization is seen as 
a fundamental step in tumor progression, there is value to identifying anti-angiogenic therapies 
that target both angiogenesis and vasculogenesis as an approach to treat cancer. 
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1.4 VASCULAR ENDOTHELIAL GROWTH INHIBITOR 
1.4.1 Identification 
Although the mechanism of postnatal neovascularization modulation is not fully understood, it is 
clear that there is a balance between stimulators and inhibitors acting as an angiogenic switch 
[27].  One of these inhibitors, vascular endothelial growth inihibitor (VEGI; TNFSF15; TL1A), 
is a member of the tumor necrosis factor (TNF) superfamily and can be found in the vasculature 
of many normal tissues, suggesting it plays a role in vascular homeostasis [126].  VEGI was 
discovered during an attempt to identify an autocrine inhibitor of angiogenesis.  A search of 
cDNA databases identified a novel protein specifically expressed by ECs that had sequence 
homology to the TNF superfamily (TNFSF), whose members have a diverse array of biological 
functions, including regulating the growth of normal cells by inducing apoptosis or enhancing 
cell survival and proliferation.  Hydrophobicity analysis of the protein revealed a 13-amino acid 
hydrophobic region that follows the amino terminal segment of 12 residues, with a carboxyl 
terminus on the exterior cell surface (residues 26-174), a single transmembrane domain, and a 
short cytoplasmic tail. These features are consistent with characteristics of a type II 
transmembrane protein.  The protein, with a molecular mass of 22 kD, exhibited a 20–30% 
sequence homology to other TNF family members [127], similar to the degree of conservation 
found among other members of the TNF family. This protein was subsequently found to inhibit 
EC growth, thus, it was named VEGI.  The protein is also termed TNF-like Ligand 1 (TL1) by 
some groups [128] and has received the HGMW-approved designation of TNFSF15. 
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1.4.2 Structure and Isoforms 
In 2007, Jin et al. determined the crystal structure of VEGI [129, 130].  VEGI has self-rotation 
functions with three monomers in the asymmetric unit and they are related by a 3-fold non-
crystallographic symmetry. The three monomers in the asymmetric unit form a homotrimer and 
assume a jellyroll β-sandwich, resembling the trimer structure typical of other members of the 
TNF family of ligands. Structure alignment between VEGI and other members of the TNFSF 
reveals similar length and overall structure, revealing their resemblance as predicted by their 
sequence homology [129, 130].  
To date, there are three isoforms of VEGI.  The initial isoform of VEGI that was 
characterized was designated VEGI-174.  This isoform is comprised of 174 amino acids, with 1-
25 AA residues at the N-terminus forming an intracellular and transmembrane domain, while 
residues 26-174 at the C-terminus form an extracellular domain.  Two other isoforms, VEGI- 
251 and VEGI-192, were subsequently determined and these isoforms exhibit the same 
conserved carboxyl terminal domain of 151 acid residues as VEGI-174 [126, 131, 132]. 
However, the three isoforms differ in their N-terminal regions (Figure 4) [126]. 
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Figure 4.  Gene structure of human VEGI and proposed generation of isoforms. 
Boxes with roman numerals represent exons.  The putative transcription start site is indicated by a double 
arrowhead. R denotes the 5′ untranslated sequence unique to each respective transcript.  Stippled boxes 
represent the common 3′ untranslated region. Approximate sizes of the introns are indicated. VEGI-251, 
VEGI-192, or VEGI-174 specific sequences are labeled '251', '192', or '174'. Exon IIIb encodes residues 
shared by both VEGI-251 and VEGI-192. The introns 5' of exons III and IV are dashed because the 5' 
ends or initiation sites of VEGI-192 and VEGI-174 transcripts have not yet been determined. 'COM' 
denotes the coding region of the last exon that is common to all three isoforms. Figure taken from [126]. 
 
VEGI-251 is also known as TL1A [133] and it is the longest and most abundant isoform 
of VEGI [130]. After the extracellular domain of VEGI-251 is cleaved off from the cell 
membrane by unidentified proteases, VEGI-251 possesses a putative secretory signal peptide that 
exists in soluble form and its overexpression causes apoptosis of ECs and inhibition of tumor 
growth [129].  In contrast, there was no effect of full-length VEGI-174 on tumor growth when 
overexpressed.  However, a secretable fusion protein comprising a secretion signal peptide and 
the putative extracellular domain of VEGI-174 was able to inhibit tumor growth [134, 135]. 
Further studies have shown that the solubilized extracellular domain of the three isoforms of 
VEGI is responsible for its biological activity [126, 131, 136, 137].  VEGI has also been detected 
in media conditioned by EC and in human circulation. Together, these findings support the view 
that secretion of VEGI is necessary to mediate its effect in inhibiting EC growth.  
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1.4.3 Expression 
VEGI mRNA expression is detected predominantly in ECs and VEGI gene transcripts are found 
in many adult human tissues, including placenta, lung, kidney, skeletal muscle, pancreas, spleen, 
prostate, small intestine and colon, suggesting the gene product plays a role in the function of a 
normal vasculature.  All three isoforms of VEGI have been found in human ECs, including 
HAECs, HUVECs, and human microvascular ECs.  Low levels are detected in adult bovine 
aortic endothelial (ABAE) cells and human coronary artery smooth muscle [126, 127, 138]. 
VEGI protein expression has been found at high levels in the placenta, kidney, lung and 
liver, skeletal muscle, and heart. The 7.5 kb transcript encoding VEGI-251 is expressed at high 
levels in the placenta, kidney, lung, and liver, whereas the 2 kb transcript corresponding to 
VEGI-174 is detected in liver, kidney, skeletal muscle, and heart. VEGI-174 mRNA is more 
abundant in heart, skeletal muscle, pancreas, adrenal gland, and liver, while VEGI-251 is more 
abundant in fetal kidney and fetal lung.  Both VEGI-251 and VEGI-174 were detected in 
prostate, salivary gland, and placenta [126]. The failure to detect the transcripts of this VEGI in 
other tissues may be due to a relatively small proportion of ECs in these tissues.  The expression 
pattern of VEGI suggests a tissue specific function of this novel protein. 
Although VEGI is primarily expressed in ECs, it was found that VEGI is also highly 
expressed in dendritic cells after in vitro activation and is up-regulated in Crohn's disease, 
rheumatoid arthritis, and mouse models of inflammatory bowel disease [139-141]. Furthermore, 
VEGI expression was also found in activated lymphocytes, plasma cells, and monocytes [133, 
140, 142].  
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1.4.4 Anti-angiogenic Activity 
VEGI is largely produced by ECs and it specifically induces apoptosis in ECs via an autocrine 
pathway [126, 127, 138].  Since VEGI is found in many normal and tumor tissues, it is thought 
that there is a physiological and pathological role for this unique molecule in regulating 
neovasularization. The anti-angiogenesis activity of VEGI was assessed using recombinant 
VEGI consisting of the putative extracellular domain in two angiogenesis models. In one 
angiogenesis model, ABAE cells grown on a layer of collagen gel are stimulated with FGF-2 to 
form a network of capillary-like structures.  Addition of the VEGI inhibited the proliferation of 
ABAE cells and completely inhibited the growth of capillary-like tubes [137]. In another 
experiment, human vascular ECs transfected with a VEGI-expressing plasmid exhibited a 
decreased ability to form microtubules in Matrigel [143]. The anti-angiogenic activity of VEGI 
was also examined using a modified chick embryo chorioallantoic membrane (CAM) assay in 
which new capillary vessels will grow into a collagen gel pellet placed on the CAM.   
Recombinant VEGI inhibited about 50% of the new capillary growth into the gel pellet induced 
by either FGF or VEGF [137].  Importantly, these results suggest that VEGI can inhibit 
angiogenesis regardless of the types of angiogenic stimuli.  
Interestingly, as increasing evidence points to VEGI being an endogenous inhibitor of EC 
growth, it is important to note that no inhibitory effect is detected thus far in other cell types 
using similar concentrations of VEGI [137].  VEGI has no effect on the growth of human breast 
cancer cells (MDA-MB-231 or MDA-MB-435) under similar experimental conditions performed 
on ECs. It has been shown, however, that a VEGI preparation was able to inhibit human breast 
cancer MCF7 cell growth in culture [144], although a substantially higher concentration of VEGI 
was required.  VEGI also did not inhibit the proliferation of human T-cell leukemia cells 
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(Jurkat), human Burkitts lymphoma cells (Raji), human monocytic leukemia cells (THP-1), or 
human promyelocytic leukemia cells (HL60), cells that are often responsive to the cytotoxic 
activity of the TNFs [127]. 
Studies have shown that the mechanism by which VEGI exerts its inhibitory effect on 
angiogenesis involves modulation of the EC cycle by enforcing growth arrest of quiescent ECs 
while causing proliferating ECs to undergo apoptosis [138]. By analyzing proliferating ECs, Yue 
et al. demonstrated that VEGI can induce ECs to shrink and induced blebbing of the plasma 
membrane associated with apoptosis.  Further studies demonstrated that VEGI, in addition to 
inducing apoptosis, can elicit growth arrest of ABAE cells in the G0/G1stage of the growth 
cycle.  VEGI prevents G0/G1 cells from re-entering the cell cycle in response to growth stimuli 
and early G1-growth arrest occurs.  Importantly, it was shown that cells in this VEGI-arrested 
state lacked all the hallmarks of apoptosis, such as DNA fragmentation, caspase-3 activation, and 
Annexin-V staining, which is normally seen in VEGI-treated cells that have entered the growth 
cycle[138].  Moreover, VEGI induces apoptosis via activation of the stress protein kinases, 
SAPK/JNK and p38 MAPK (SAPK, stress-activated protein kinase, JNK, c-Jun N-terminal 
protein kinase, p38 MAPK, p38 mitogen-activated protein kinase), and the caspases, mainly 
caspase-3- like protease [138].   
The activity of VEGI has been postulated to arise from its interaction with members of 
the TNF receptor superfamily.  VEGI is a ligand for two TNF receptors, namely death receptor 3 
(DR3) and decoy receptor 3 (DcR3).  Previously, there has been evidence indicating DR3 is the 
functional receptor of VEGI 251 [133].  It contains a death domain in its cytoplasmic tail and 
VEGI induces apoptosis in DR3 expressing cell lines, such as in HUVECs, reducing 
angiogenesis.  In contrast, it has been indicated that DcR3 enhances angiogenesis by blocking the 
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autocrine function of VEGI [142].  DcR3 is over-expressed in malignant tumors arising from 
oesophagus, stomach, glioma, lung, colon, and rectum [130, 140-142].  Direct interactions 
between VEGI and both DR3 and DcR3 has been detected either by co-immunoprecipitation or a 
flow cytometry based assay [133, 145].  Consistently, the use of anti-VEGI or anti-DR3 
antibodies lead to increases of cell proliferation and motility, resulting in induced formation of a 
capillary network [146].  The angiogenic effect of VEGI antibody and DR3 antibody is similar to 
that induced by DcR3.  
1.4.5 Anticancer Activity 
The unique characteristics of VEGI suggest it may be an ideal candidate for the treatment 
of pathological angiogenesis.  Pathological angiogenesis, as seen in growing tumors, is 
prolonged and uncontrolled once initiated, and can be due to the absence or suppression of a 
physiological inhibitor like VEGI.  Treatment of tumors with VEGI may allow proliferating 
vasculature to undergo apoptosis while leaving normal quiescent vessels unaffected. In parallel 
with this thought, recombinant VEGI has been shown to be a highly potent inhibitor of EC 
proliferation in tumors, resulting in specific elimination of ECs in tumor vasculature and 
inhibition of angiogenesis [131].  More importantly, VEGI treatment of tumor cells showed no 
overt toxicity to ECs of the normal vasculature in other tissues [131].  Furthermore, it was found 
that VEGI was able to markedly inhibit tumor formation and growth in a variety of angiogenesis 
and cancer models [127, 137].  
Xenograft tumor models were used to assess the anti-angiogenic ability of VEGI.  Highly 
tumorigenic breast cancer cells (MDA-MB-231 or MDA-MB-435) were mixed with VEGI-
overexpressing Chinese hamster ovary (CHO) cells and injected into the mammary fat pads of 
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athymic nude mice.  Growth of the xenograft tumors was monitored and despite the high 
tumorigenicity of the breast cancer cell lines used, marked inhibition of tumor growth was 
observed. A repeat experiment with MDA-MB-435 revealed a complete inhibition of tumor 
formation.  Vector-transfected CHO cells had no effect on tumor growth in either case [137].  
Since VEGI does not inhibit the growth of these breast cancer cells in culture, the anticancer 
activity of the protein most likely derives from its anti-angiogenic activity.  The anticancer 
activity of VEGI-overexpressing CHO cells was also studied in a prostate cancer animal model. 
The CHO cells were mixed with prostate cancer cells (PC3) at various ratios (10:1, 5:1, 1:1 and 
0:1) before being subcutaneously injected into athymic nude mice.  Initially, the tumors grew, 
but then disappeared in the groups with higher ratios of CHO:PC3. PC3 cells implanted alone 
exhibited progressive tumor growth [137]. The results indicate that higher levels of VEGI may 
cause the elimination of established tumors. 
While VEGI is normally expressed in the vascular ECs of many adult tissues, it has been 
reported that VEGI is absent or expressed at low levels in tumors vasculatures of breast cancer 
[134], prostate cancer [147], and urothelial cancer [148], supporting the idea that VEGI is a 
negative regulator of neovascularization.  It was also reported that patients with breast cancer 
that expressed reduced levels of VEGI had a higher local recurrence, shorter survival time and an 
overall poorer prognosis compared to patients expressing higher levels of VEGI [134].  The 
lowered expression of VEGI in tumors and the ability of recombinant VEGI to specifically 
suppress tumor angiogenesis make VEGI a promising anticancer agent.  However, it is yet 
unknown whether VEGI is able to inhibit tumor vasculogenesis.  
 29 
1.5 PURPOSE 
This research will be a first step in understanding the role of VEGI in modulating tumor 
vasculogenesis. While VEGI inhibits angiogenesis by specifically inhibiting EC proliferation and 
inducing apoptosis, it is unknown whether VEGI can inhibit EPC-supported vasculogenesis.  
Given that tumor vasculature arises from both angiogenesis and vasculogenesis, with EPCs being 
the activator of the angiogenic switch, it is highly significant to determine whether VEGI can 
also inhibit EPC-supported vasculogenesis.  If VEGI is able to exert an inhibitory function not 
only on mature differentiated ECs but BM-derived EPCs as well, it may prevent EPCs from 
participating in tumor vasculogenesis.  This could lead to further elimination of the tumor 
vasculature resulting in profound inhibition of tumor formation, growth, or metastasis. Our goal 
is to determine the changes that occur in BM-derived EPC-supported tumor vasculogenesis in 
response to VEGI treatment.  In addition, the proposed research could yield important insights 
into the function of VEGI in postnatal vasculogenesis, advancing the understanding of the 
pathobiology of tumor neovascularization and helping to facilitate the development of 
therapeutic uses of VEGI in cancer. 
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2.0  VEGI INHIBITS BM-DERIVED EPC DIFFERENTIATION AND FUNCTION IN 
VIVO 
 
2.1 ABSTRACT 
Bone marrow (BM)-derived endothelial progenitor cells (EPCs) have been shown to have a 
critical role in supporting de novo formation of blood vessels during postnatal and tumor 
vasculogenesis.  Vascular endothelial growth inhibitor (VEGI; TNFSF15; TL1A) is an 
endogenous inhibitor of angiogenesis that specifically induces apoptosis of proliferating 
endothelial cells (ECs).    However, it is unknown whether VEGI is able to modulate BM-
derived EPCs as well.  We report here that VEGI inhibits the differentiation of BM-derived cells 
into EPCs under EC stimulating culture conditions.  Bone marrow cells cultured in the presence 
of VEGI showed a significant decrease in expression of EC surface markers that was coupled 
with a diminished ability of the cells to migrate, adhere, and form capillary-like structures critical 
for neovascularization.  Additionally, VEGI was found to activate cell growth signaling and 
inhibit cell differentiation signaling in early stage EPCs.  In contrast, VEGI treatment decreased 
the number of adhered cells in culture by inducing apoptosis in late stage differentiated EPCs.  
Moreover, the apoptosis of BM-derived EPCs in response to VEGI treatment is mediated by 
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death receptor-3 (DR3), which is expressed only in late stage EPCs, and antibodies that 
neutralize DR3 inhibits VEGI induced apoptosis.  These findings indicate that VEGI plays a 
biologically significant role in postnatal vasculogenesis by negatively modulating differentiation 
of BM-derived cells into EPCs. 
2.2 INTRODUCTION 
Until a decade ago, it was thought that postnatal neovascularization, the proliferation, migration 
and stabilization of new blood vessels, occurred solely via angiogenesis, the process of capillary 
sprouting from pre-existing blood vessels [22].  Since then, bone marrow (BM)-derived 
endothelial progenitor cells (EPCs) have been discovered and found to contribute to postnatal 
neovascularization via vasculogenesis, the de novo formation of new vessels [11, 19, 82, 149, 
150].  There are two populations of EPCs in culture, termed early and late EPCs, which differ in 
their morphology and have distinct patterns of cell growth.  As EPCs differentiate from early to 
late stage EPCs, they lose their progenitor characteristics and gain endothelial characteristics.  To 
date, there is no exclusive EPC marker, however EPCs have been commonly identified by the 
co-expression of stem and endothelial cell (EC) surface markers, including CD133, Sca-1, Flk-1, 
Tie-2, E-selectin and VE-cadherin [48, 151].   
Under normal conditions, EPCs are in a quiescent state within the bone marrow niche and 
their numbers in the circulating blood are very low. However, trauma to the endothelium during 
occurrences such as tumor development, wound injury or ischemia, induces EPCs migration 
from the bone marrow into the periphery, resulting in increased EPC numbers in the blood [68, 
72].  Many stimulating growth factors and cytokines have been shown to activate signaling 
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molecules which induce the migration and differentiation of EPCs [81, 152, 153].  One such 
signaling factor, Akt, modulates the expression of adhesion molecules and controls EPC homing 
and migration [99].  Akt also plays a role in modulating EPC differentiation into mature ECs 
[154].  However, cytokines that negatively regulate EPC differentiation are not as well known. 
Vascular endothelial growth inhibitor (VEGI; TNFSF15; TL1A) is a member of the 
tumor necrosis factor (TNF) superfamily and plays a vital role in maintaining vascular 
homeostasis.  VEGI is an endogenous inhibitor that is primarily expressed by vascular ECs to 
inhibit their proliferation [127].  Specifically, VEGI enforces growth arrest of quiescent ECs in 
G0 and G1 phases of the cell cycle, while inducing apoptosis of proliferating ECs, thereby 
inhibiting angiogenesis [137, 138, 155].  It has also been demonstrated that VEGI activates T-
cells [133, 156, 157] and stimulates the maturation of dendritic cells [158], indicating VEGI 
helps modulate the interaction between the endothelium and the immune system.  The inhibitory 
activity of VEGI has been shown to occur via mitogen-activated protein kinases (MAPKs) and 
the caspases [138].  Furthermore, the activity of VEGI has been thought to be due to its 
interaction with death receptor 3 (DR3), a member of the TNF receptor superfamily [133, 159].  
In this study, we examine whether VEGI has an inhibitory effect on BM-derived EPC.  
We found that VEGI can inhibit the differentiation of bone marrow stem cells into EPCs, 
resulting in obstructed migration and adhesion of these cells in culture.  Additionally, we found 
that VEGI induces apoptosis of differentiated BM-derived EPCs.  These findings provide 
important insights into the modulation of BM-derived EPC differentiation and function. 
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2.3 MATERIALS AND METHODS 
2.3.1 Antibodies and reagents  
Anti-DR3 antibody, fluorochrome-conjugated anti-mouse Sca-1, Flk-1, Tie-2, E-selectin, VE-
cadherin, CD31, CD117 and AC133 antibodies were purchased from eBioscience (San Diego, 
CA). The antibodies for total or phosphorylated p38, Akt and Erk were purchased from Cell 
Signaling Technology (Danvers, MA). Integrin α5, integrin αv, Flk-1, Tie-2, E-selectin, VE-
cadherin, AC133, CD117, and DR3 antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Alexa Fluor Dyes conjugated secondary antibody, Calcein Acetoxymethyl and 
fluorescent phallotoxin were purchased from Invitrogen Corporation (Carlsbad, CA). VEGF, 
fibronectin, and Matrigel were purchased from R&D Systems (Minneapolis, MN). ECM Cell 
adhesion array kit and Chemicon QCMTM cell migration assay kit were purchased from 
Millipore (Billerica, MA). Caspase-3/CPP32 Colorimetric Assay Kit was purchased from 
BioVision Research (Mountain View, CA). VEGI isoform VEGI-192 was prepared as described 
[131]. One unit of VEGI activity equals the concentration of VEGI required for half-maximum 
inhibition of bovine aortic EC growth in culture, known as the IC50 [155]. The endotoxin level 
in the VEGI preparation is 25 ng/mg, with the final endotoxin concentration in cell cultures of 
0.025 ng/ml. 
 34 
2.3.2 Mice 
Eight-week old female C57BL/6 mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME). All experiments involving animal subjects were performed in accordance with the 
University of Pittsburgh Institutional Animal Care and Use Committee approved protocols. 
2.3.3 Cell Preparation 
Whole bone marrow stem cells were isolated from the femurs and tibia of adult mice via bone 
marrow flush. Cells were first lysed with ACK cell lysis buffer (Lonza, Walkersville, MD)  and 
then purified for the Sca-1+ population using biotin conjugated Sca-1 antibody and a biotin 
magnetic selection kit (StemCell Technologies).  6 x 106 cells/well were placed in 10 µg/ml 
fibronectin-coated 6-well plates and cultured in endothelial growth medium (EGM-2) 
supplemented with a bulletkit containing EGF, hydrocortisone, VEGF, FGF-B, heparin, IGF, 
gentamicin and 5% heat-inactivated fetal bovine serum (all from Lonza, Walkersville, MD). 
2.3.4 Flow cytometry 
5 x 105 cells were collected per sample and washed with 2 ml of fluorescence-activated cell 
sorter (FACS) buffer (1% BSA and 0.05% sodium azide in PBS).  After washing, the cells were 
resuspended in 100 µl of FACS buffer containing 1 µg of the indicated antibody, dispensed in a 
minimum of 1 x 105 cells per sample, gently mixed, and incubated on ice for 30 minutes.  The 
cells were washed with FACS buffer, resuspended in PBS and analyzed within 1 hour using 
Coulter FACS equipment and EXPO analysis software (Beckman Coulter, Fullerton, CA). 
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2.3.5 Cell adhesion assay 
One-week cultured EPCs treated in the absence or presence of VEGI were collected and re-
plated (0.2 x 106 cells/100 µl) on 96-well plates coated with extracellular matrix proteins 
(Chemicon ECM adhesion Kit), then cultured for 2 hours.  The wells were gently washed with 
PBS and any adherent cells remaining in the wells were stained with crystal violet for 10 
minutes. After washing and extraction, the absorbance at 560nm was determined by a 
spectrophotometer. 
2.3.6 Cell migration assay  
Cultured cells with or without VEGI treatment were reseeded into the upper chamber of a 
Modified Boyden Chamber (Chemicon QCM Cell migration kit) containing serum and growth 
factor free culture media (0.2 x 106 cells/100 µl). Stimuli were added into the lower chamber and 
the cells were allowed to migrate for 8 hours.  Migrated cells were collected, lysed, and dyed 
with CyQunat GR to analyze absorbance at 480/520nm using a fluorescence plate reader.  In the 
wound-healing assay, a strip of cells was removed with a sterile pipette tip from the cell 
monolayer of 10 day cultured EPCs.  The migration of cells into the empty space was recorded 
for 48 hours. 
2.3.7 Tube formation assay 
A Matrigel tube formation assay was performed as described [160].  Cultured EPCs with or 
without VEGI treatment were re-plated in a 48-well culture plate coated with Matrigel 
 36 
containing 100 ng/ml of VEGF (5x104 cells/well).  After 20 hours, microscopic images of 
vascular structural tubes formed by the cells were taken.  Total tube length was determined using 
Image J software (NIH). 
2.3.8 Cellomics Array Scan 
Using 96-well black plates, 3 x 103 cells/well were cultured in the absence or presence of VEGI, 
and then fixed with 4% paraformaldehyde for 20 minutes at room temperature.  Cells were 
permeabilized in PBS containing 0.1% Triton X-100 for 5 minutes, washed with PBS, then 
blocked with 3% BSA for 30 minutes.  Cell surface markers and adhesion signal proteins were 
labeled with primary antibody and fluorescent dye conjugated secondary antibody. Nuclei were 
stained with Hoechst.  Images of the cells were taken and analyzed for fluorescence density in 
the cytoplasm and nucleus by Cellomics array scan (ArrayScan VTI HCS Reader, Cellomics 
Inc., Pittsburgh, PA). 
2.3.9 Cell proliferation and viability assay  
Purified Sca-1+ bone marrow cells were cultured with or without VEGI.  Adherent and 
suspended cell populations were collected separately on various days of culture. To evaluate cell 
proliferation and viability, cells were dyed with Calcein Acetoxymethyl (Molecular Probes) at 2 
µM and incubated for 1 hour.  The cells were washed, and absorbance was read at 480/520nm 
with a fluorescence plate reader.   
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2.3.10 Cell apoptosis assay 
Adherent and suspended cells were collected separately, and then centrifuged onto slides using a 
Cytocentrifuge (Shandon Cytospin 3 Centrifuge). The cells were washed and fixed with 4% 
paraformaldehyde in PBS, then permeabilized with 0.1% Triton X-100 in PBS for 2 minutes on 
ice.  After blocking with 3% BSA, the cells were labeled for DNA strand breaks by a TUNEL 
assay kit (Roche). The cells were also labeled with anti-E-selectin primary antibody and 
fluorochrome-conjugated secondary antibody. Nuclei were stained with Hoechst and the cells 
were then sealed with anti-fading agent for 24 hours and analyzed with a fluorescent microscope 
(Nikon Eclipse E800, Japan).   
2.3.11 Caspase-3 activity assay 
Caspase-3/CPP32 Colorimetric Assay Kit (Mountain View, CA) was used to analyze caspase-3 
activity. Cells were first lysed using cell lysis buffer for 2 hours at 4ºC on a shaker. Plates were 
then centrifuged and cleared lysates were transferred to a new 96-well plate. Cleared cell lysates 
were incubated with caspase-3 reaction buffer and substrate DEVD-pNA. The chromophore p-
nitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA was detected at 405 nm 
by Benchmarked Plus spectrophotometer (BioRad, Hercules, CA). 
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2.3.12 Immunofluorescence staining   
Cells were washed and fixed with 4% paraformaldehyde in PBS at room temperature for 20 
minutes, then permeabilized with 0.1% Triton X-100 in PBS for 5 minutes.  Samples were 
washed with PBS, blocked for non-specific antibody binding with 3% BSA for 30 minutes, 
followed by incubation with primary antibodies for 1 hour at room temperature.  After 5 washes 
with PBS, cells were incubated with fluorochrome-conjugated secondary antibodies for 1 hour.  
After nuclei staining with Hoechst, the cells were sealed with anti-fading agent for 24 hours and 
analyzed with a fluorescent (Nikon Eclipse E800, Japan) or confocal (Olympus Fluoview 1000, 
Japan) microscope.  
2.3.13 Western blot analysis    
Cells were collected and lysed.  Proteins in the cell homogenate were then resolved using SDS-
PAGE.  Next, the proteins were transferred onto a Hybond-ECL nitrocellulose membrane and 
blocked with 5% nonfat dry milk powder in TBS-T buffer (20 mM Tris-HCl, pH 7.4, 137 mM 
NaCl, and 0.1% Tween) for 1 hour at room temperature.  After blocking, the membrane was 
incubated with primary antibodies against the targeted protein and stored overnight at 4°C. The 
membrane was washed with TBS-T and incubated with the corresponding HRP-conjugated 
secondary antibody for 1 hour at room temperature.  After another wash with TBS-T, the 
membrane was developed using the ECL System (Amersham Pharmacia Biotech, Arlington 
Heights, IL).  
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2.3.14 Statistical analysis 
Results shown are the mean ± SE of a minimum of three separate experiments. Student’s t-test 
for independent samples was used to compare data between experimental groups. Values of 
P<0.05 were considered statistically significant and are indicated with an asterisk. 
2.4 RESULTS 
2.4.1 Characterization of mouse BM-derived EPC 
Whole bone marrow from C57BL/6J mice was purified for the Sca-1+ cell population.  Once 
purified, the bone marrow cells were cultured in EC growth media to facilitate the differentiation 
of EPCs.  After two weeks of culture, the cells had adhered to the culture plates, become 
confluent, and elongated in shape, mirroring EC morphology (Figure 5). 
 
 
 
 
 
 
 
Figure 5.  Morphology changes of BM-derived EPCs in culture.  
Phase-contrast images of cultured Sca-1+ bone marrow cells over two weeks show progressive 
differentiation of BM-derived EPCs (20x objective lens). 
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Flow cytometric analysis revealed the cells expressed a concurrent change in the 
expression pattern of cell surface markers.  Day 0 to day 14 cells were stained for expression of 
stem cell markers Sca-1, CD117 and AC133 and EC markers Flk-1, Tie-2 and E-selectin.  
Consistent with the initial morphology change that bone marrow cells undergo within 7 days, it 
was seen that one-week cultured cells possessed both EC markers and stem cell markers (Figure 
6A).  We found that over the continued course of culture, stem cell marker expression decreased.  
However, EC marker expression increased in the same two-week cell cultures, indicating cells 
were differentiating toward ECs (Figure 6A).  Looking at protein expression levels, it is also 
observed that EC markers begin to be expressed in later cultures (Figure 6B). 
Immunofluorescence staining confirmed EC marker expression on day 14 cultured cells (Figure 
6C).  These changes in cell morphology and surface marker expressions indicate bone marrow 
cells were able to differentiate into EPCs around day 7 of cell culture. 
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Figure 6.  Expression pattern of BM-derived EPC surface markers. 
A.  Histograms of stem and EC marker expressions on day 0, 3, 7, 10 and 14 cultured cells. B.  Protein 
level of EC markers in EPC cultures shown by Western blot analysis.  C.  Immunofluorescence staining 
for EC markers on day 14 cultured cells. Green, VE-cadherin; Red, E-selectin; Blue, cell nuclei.   
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2.4.2 VEGI inhibits EC marker expression on BM-derived EPC 
To determine the effect of VEGI on the differentiation of BM-derived EPCs, purified Sca-1+ 
bone marrow cells were cultured in the presence or absence of VEGI.   After 10 days of culture, 
control cells differentiated into elongated spindle shaped cells reminiscent of ECs and adhered to 
the culture plates.  Meanwhile, the majority of VEGI-treated cells maintained a small circular 
appearance, still resembling bone marrow cells (Figure 7).  Accordingly, VEGI treatment 
impacted the expression of EPC surface markers.  In control cell cultures, Flk-1 and E-selectin 
expression significantly increased from day 3 to day 10.  However, cells treated with VEGI did 
not display the same increased expression of Flk-1 and E-selectin.  There was no difference in 
the expression of stem cell marker, Sca-1, between the two groups (Figure 8). 
 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  VEGI inhibits differentiation of BM-derived EPC in culture.  
Phase-contrast images show a morphological difference between cultured EPCs in the absence or 
presence of VEGI for 10 days. 
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Figure 8.  VEGI treatment decreases expression of EC markers. 
Histograms from flow cytometric analysis of stem cell marker (Sca-1) and EC marker (Flk-1 and E-
selectin) expression on BM-derived EPCs cultured in the absence or presence of VEGI.  White areas, 
untreated; Shaded areas, VEGI-treated. 
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To confirm the change found in surface marker expression resulting from VEGI 
treatment, we immunostained day 3 and day 10 cultures with fluorescence-conjugated 
antibodies.  We labeled multiple surface markers, including Flk-1, with their respective 
antibodies, as well as labeled F-actin to examine the cytoskeleton (Figure 9A).  Analysis of the 
fluorescence intensity of stem cell markers Sca-1 and AC133 reveals that from day 3 to day 10, 
stem cell marker expression is decreased in both control and VEGI-treated cultures.  However, 
while expression of EC markers Flk-1, Tie-2, E-selectin and VE-cadherin was found to increase 
in control cells, VEGI treatment significantly inhibited the expression of EC markers in day 10 
cultures.  Compared to untreated control cells, VEGI treatment resulted in a 50% decrease of EC 
marker expression, on average (Figure 9B).   These results indicate that VEGI inhibits the 
differentiation of BM-derived EPC in culture by down-regulating EC gene expression.  
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Figure 9.  Analysis of fluorescence intensity of EPC markers. 
A.  Confocal microscopic images of immunofluorescence stained EC marker Flk-1 on EPCs cultured for 
10 days in the absence or presence of VEGI (20x objective lens). Green, Flk-1; Red, actin; Blue, cell 
nuclei.  B. A total of 3000 cells per well were analyzed for fluorescence intensity of various 
immunostained stem and EC markers. 
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2.4.3 VEGI inhibits EPC migration and formation of capillary-like structures  
To determine whether VEGI has any impact on the function of BM-derived EPCs, we first 
examined the ability of the cultured cells to migrate.  Sca-1+ bone marrow cells were cultured in 
the presence or absence of VEGI for 10 days, then collected and reseeded.  Next, utilizing the 
wound-healing assay, a scratch was made through the cell culture monolayer and cells were 
allowed to migrate for 48 hours.  Control cells were capable of migrating into the wound and 
repopulating the exposed space.  However, VEGI treatment inhibited the migration of the 
cultured cells, and as a result, VEGI-treated cells were unable to refill the open wound (Figures 
10A, 10B). Additionally, the migration ability of EPCs on day 7 was determined using transwell 
chambers.  After 8 hours, we observed that about 25% more cells migrated through the filters in 
control cultures than in VEGI-treated cultures (Figure 10C).  
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Figure 10.  VEGI inhibits BM-derived EPC migration. 
A. Phase-contrast images of cell migration into an open wound space. Solid line, wound edge; Dashed 
line, front edge of cell migration. B. Relative distance between the wound edge to the front edge of the 
migrating cells. C. Relative migration rate of BM-derived EPCs through a porous barrier in a transwell 
assay. 
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Next, we determined the ability of BM-derived EPCs to assemble into vascular networks 
on a reconstituted basement membrane.  BM-derived EPCs in the control group were capable of 
forming capillary-like structures when placed on Matrigel (Figure 11A). Cells cultured in the 
presence of VEGI, however, exhibited an inability to form similar structures (Figures 11A, 11B).  
These results indicate that VEGI has an inhibitory effect on the migration abilities characteristic 
of differentiated ECs. 
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Figure 11.  VEGI inhibits capillary-like tube formation. 
A. Phase-contrast images of the formation of capillary-like structures by BM-derived EPCs. Cells 
cultured for 2 weeks in the absence or presence of VEGI were placed on Matrigel and allowed 24 hours 
for tube formation. B. Measurement of the total length of the capillary-like tubes after 24 hours. 
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2.4.4 VEGI inhibits EPC from adhering to fibronectin and vitronectin  
To analyze the ability of BM-derived EPCs to adhere to a surface, freshly purified Sca-1+ cells 
were cultured for one week in the presence or absence of VEGI, then collected and reseeded into 
culture plates coated with a battery of extracellular matrix proteins.  Two hours after reseeding, 
we found that EPCs adhered best to fibronectin and vitronectin; however, adhesion to both these 
matrix proteins was reduced significantly in VEGI-treated cells (Figure 12).  Additionally, when 
the cells adhered on fibronectin, the phosphorylation of cell adhesion molecules, FAK, paxillin, 
and Src, in the untreated control cells was 2-times that of VEGI-treated cells (Figure 13). 
 
 
Figure 12.  EPC adhesion to extracellular matrix proteins. 
The ability of EPCs cultured for 7 days to adhere on surfaces coated with the indicated extra-cellular 
matrix proteins in the presence or absence of VEGI. 
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Figure 13.  VEGI decreases cell adhesion signaling in EPCs. 
EPC cultured for 10 days in the absence or presence of VEGI were immunostained for cell signaling 
molecules involved in adhesion and fluorescence intensity was analyzed. 
 
We then examined the expression of integrin α5 and αv to see whether the decreased 
adhesion resulting from VEGI treatment was due to a decline in α5β1 and αvβ3, the receptors of 
fibronectin and vitronectin.  Using immunofluorescence staining, we determined that 
morphologically, the integrin proteins formed clusters in focal adhesion structures only in the 
control group (Figure 14A).  We analyzed the fluorescence intensity of the cells and found a 
significant decrease of integrin expression in VEGI-treated cultures.  VEGI treatment yielded a 
3-fold decrease in α5 expression and a 2-fold decrease in αv expression compared to controls 
(Figure 14B).  These results suggest that VEGI inhibits BM-derived EPCs adhesion by inhibiting 
activation of signaling molecules and receptors involved in cell adhesion. 
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Figure 14.  VEGI inhibits integrin expression on BM-derived EPCs. 
A. Confocal microscopic images of immunofluorescence staining for integrins on EPCs cultured for 10 
days in the absence or presence of VEGI. Green, integrin αv; Red, integrin α5; Blue, cell nuclei. B. 
Fluorescence intensity of integrins α5 and αv immunostaining.   
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2.4.5 Effect of VEGI on EPC viability and apoptosis 
Given the diminished ability of BM-derived EPC to adhere when treated with VEGI, we 
examined the number of cells remaining suspended vs. becoming adhered in the presence of 
VEGI over a two-week culture.  There is an increased number of suspended cells in VEGI-
treated cultures during the first week (Figure 15A), but no difference was seen in the number of 
adhered cells (Figure 15B).  During the second week of culture, while the number of suspended 
cells in both groups decline (Figure 15A), only the cells in the control group became adherent.  
In contrast, the number of adhered cells in the VEGI-treated group decreases substantially 
(Figure 15B).   
 
A          B 
 
 
 
 
 
 
 
Figure 15.  VEGI inhibits BM-derived EPC adhesion in culture.  
A.  The number of suspended cells and B. the number of adhered cells in EPC cultures measured by 
relative fluorescence units (RFU) of Calcein-AM staining.   
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To investigate the cause of the diminishing population of suspended and adhered cells in 
the VEGI-treated cultures, we analyzed the amount of apoptosis occurring in the cell cultures 
after one week.  We stained the suspended and adhered cell population of control and VEGI-
treated cultures for E-selectin to assess EPC differentiation and TUNEL to assess apoptosis 
(Figure 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Relationship between EPC differentiation and apoptosis. 
Fluorescence images of suspended and adherent cells undergoing differentiation or apoptosis at various 
time points as indicated.  Red, TUNEL; Green, E-selectin; Blue, cell nuclei. 
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The total percentage of apoptosis in the adhered cell population of both the control group 
and VEGI-treated group was very low on day 7.   However, while apoptosis rates in the control 
group did not increase, apoptosis rates in the VEGI-treated group increased 40% and 95% on 
days 11 and 14, respectively (Figure 17).  In the suspended cell population, apoptotic cells were 
present regardless of VEGI-treatment.  Interestingly, there was significantly less apoptosis in the 
VEGI-treated group only on day 7 (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  VEGI induces apoptosis of adhered cells. 
Apoptosis rates of suspended cells and adhered cells in the presence or absence of VEGI, analyzed at 
various time intervals as indicated. 
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When we examined the fluorescence intensity of E-selectin, we found that in adhered 
cells, the expression level increased in control cultures from day 7 to 14.  However, treatment 
with VEGI significantly prevented the expression of E-selectin compared to control cells (Figure 
18).  There was a low level of E-selectin in all suspended cells, suggesting this population of 
cells did not differentiate into EPC.  Interestingly, the expression of E-selectin on day 7 
suspended cells was significantly lower in the VEGI-treated group (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  VEGI downregulates expression of E-selectin in adhered cells. 
Fluorescence intensity of E-selectin positive EPCs analyzed at various time intervals as indicated. 
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Since we saw a marked decrease in apoptosis and E-selectin levels in day 7 suspended 
cells of the VEGI-treated group, we further analyzed the relationship between apoptosis and E-
selectin expression on this suspended cell population (Figure 19). We found that in untreated 
controls, E-selectin positive cells did not undergo apoptosis, but E-selectin negative cells were 
almost completely apoptotic.  Conversely, in VEGI-treated cells, E-selectin positive cells had a 
significant increase in apoptosis rates and E-selectin negative cells had a significant decrease of 
apoptosis rates (Figure 19). Together, these results demonstrate that VEGI has a slight protective 
effect on early-stage undifferentiated cells, but induces apoptosis of late-stage differentiated 
EPCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  VEGI specifically induces apoptosis of E-selectin positive cells. 
Apoptosis rates of E-selectin positive or negative cells in EPC cultures on day 7. 
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2.4.6 VEGI activates caspase-3 in late stage EPC 
In order to determine the molecular mechanism of VEGI induced apoptosis on late stage BM-
derived EPCs, we first examined expression levels of DR3 on differentiating EPC cultures. 
Western blot analysis revealed DR3 begins to be expressed around day 6 and increases markedly 
as BM-derived EPCs continue to differentiate toward ECs (Figure 20).  
 
 
 
 
 
 
Figure 20.  BM-derived EPCs express DR3.  
Western blot showing increased DR3 expression in BM-derived EPC over 10 days of culture. 
 
The increase in DR3 expression coincides with the increase of apoptosis seen in BM-
derived cells in response to VEGI.  To determine whether DR3 mediates the apoptotic effect in 
response to VEGI treatment, we examined caspase-3 activity to measure apoptosis of BM-
derived EPCs cultured for 12 days.   Caspase-3 activity was very low in EPC cultures on days 4 
and 6 at all dosages of VEGI treatment.  In contrast, there was a significant dose-dependent 
increase of caspase-3 activation on days 8 and 12 (Figure 21A).  Using antibodies that neutralize 
DR3, caspase-3 activation in response to VEGI treatment was inhibited on days 8 and 12, while 
no effect was seen on days 4 and 6 (Figure 21B). These results indicate that DR3 likely mediates 
the apoptotic activity of VEGI on differentiated BM-derived EPCs. 
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Figure 21.  VEGI-induced apoptosis mediated by DR3.   
A.  Caspase-3 activation in EPC cultures induced with various concentrations of VEGI.  B. Inhibition of 
VEGI-induced caspase-3 activation using DR3 neutralizing antibodies. Asterisk indicates P < 0.05 
compared with untreated cells. Pound sign indicates P < 0.05 compared with VEGI-treated cells.   
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2.4.7 VEGI inhibits Akt, activates Erk and p38 in early stage EPC 
To understand the molecular mechanism underlying the activity of VEGI on early stage cells, the 
activation of three important MAPKs (ErK, p38 and Akt) which modulate cell differentiation and 
growth was determined.  We treated freshly purified Sca-1+ bone marrow cells with VEGI for 15 
minutes to examine immediate early responses.  We found a dose-dependent increase of 
phosphorylated Erk and p38 (Figure 22). In contrast, there was a dose-dependent inhibition of 
Akt phosphorylation (Figure 22). These findings indicate that VEGI activates cell growth signals 
and inhibits cell differentiation signals in early stage EPC cultures.  
 
 
 
 
 
 
 
 
Figure 22.  Cell signaling changes induced by VEGI treatment in early EPCs. 
Western blots showing the phosphorylation of Erk, Akt or p38 in freshly purified Sca-1+ cells treated with 
various concentrations of VEGI for 15 minutes. 
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2.5 CONCLUSIONS 
Neovascularization occurs via two pathways, angiogenesis and vasculogenesis.  It has been 
shown that the process of vasculogenesis involves numerous growth factors that stimulate BM-
derived EPC differentiation and migration to sites requiring vascularization [81, 89, 161, 162].  
However, inhibitors of BM-derived EPC modulation are not well known.  The discovery of an 
inhibitor of BM-derived EPCs is of value to understanding the regulation of post-natal 
vasculogenesis supported by EPCs.  The data we show here indicate that VEGI, an endogenous 
cytokine, can inhibit differentiation of mouse BM-derived EPCs in culture, resulting in disrupted 
function of these cells and preventing formation of new vascular structures.   
Bone marrow stem cells cultured under EC growth conditions can be divided into two 
distinct populations of cells, early and late stage EPCs.  Early stage EPCs are also known as bone 
marrow EPCs, immature EPCs or vascular stem cells [31, 48, 163].  During the initial days of 
culture, we observe that most early stage EPCs are suspended in the culture medium and express 
a low level of EC surface markers. As cells differentiate toward late stage EPCs, they become 
adhered to the culture plates and express increased levels of EC markers Flk-1, Tie-1, E-selectin, 
and VE-cadherin, while their overall stemness decreases.  Accordingly, the morphology of the 
cells elongate to resemble spindle shaped ECs. However, VEGI treatment inhibits the 
differentiation of early stage to late stage EPCs.  We found that VEGI-treated cells do not 
express increased EC markers like their control counterparts, nor do they change 
morphologically. Compared to control cells, the level of EC marker expression in VEGI-treated 
cells was about 30% to 50%, indicating VEGI significantly inhibited BM-derived EPC 
differentiation. 
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Besides the observed inhibitory effect on morphology and EC marker expression, cells 
treated with VEGI also displayed decreased EPC functionality.  VEGI-treated cells had a 
dramatic inhibition in migration across both a flat surface and through a porous membrane.  In 
conjunction, VEGI-treatment resulted in almost a complete abolished ability of the cells to form 
capillary-like tubes on Matrigel.  Moreover, the ability of VEGI-treated cells to adhere to 
extracellular matrix proteins, fibronectin and vitronectin, declined significantly as well.  The 
stunted adhesion capability is likely due to the concurrent VEGI-induced inhibition of integrin 
α5β1 and αvβ3 expression, which are the known receptors of fibronectin and vitronectin, and the 
inhibition of phosphorylated adhesion signaling molecules, FAK, paxillin, and Src.  Inhibiting 
integrin expression may be one mechanism by which VEGI negatively modulates BM-derived 
EPC differentiation, as integrins have been shown to play an important role in EPC 
differentiation and homing [164-166]. 
By inhibiting adhesion in EPC cultures, VEGI-treatment maintains early stage EPCs in a 
suspended state.  We found that many of the suspended cells found in day 7 cultures are also 
devoid of E-selectin expression, indicating the cells are undifferentiated.  Additionally, these 
cells appear to undergo less apoptosis on day 7 compared to suspended control cells, indicating 
VEGI may have a transient protective effect on early stage undifferentiated EPCs.  Conversely, 
VEGI treatment induced apoptosis in the adhered cell population. While the adhered cells in 
untreated controls remained viable and expressed high levels of E-selectin, indicating the cells 
had differentiated into EPCs, the adhered cells in VEGI-treated cultures had up to a 100% 
apoptosis rate by day 14, therefore inhibiting late stage EPC differentiation. These results 
indicate early stage and late stage EPCs have very different responses to VEGI. 
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The apoptosis activity in late stage EPCs as a result of VEGI treatment may be mediated 
by DR3, shown to be the receptor of VEGI in certain immune cells [133, 159].  We examined 
DR3 expression in EPCs and found that DR3 begins to emerge around one week of culture and 
continues to increase substantially by day 10.  This timing of DR3 expression coincides with the 
onset of increased EPC apoptosis rates in VEGI-treated cultures.  Furthermore, VEGI treatment 
induced caspase-3 activity only in EPCs cultured for more than 6 days.  More importantly, 
antibodies that neutralize DR3 were able to inhibit caspase-3 activity in late stage EPCs treated 
with VEGI. 
The mechanism behind the inhibitory activity observed in early stage EPCs appears to be 
DR3 independent, as early stage EPCs have not yet begun to express DR3.  VEGI not only 
inhibits differentiation of early stage EPCs, but also protects them from undergoing apoptosis to 
a certain degree.  As a result, we examined protein kinases involved in cell differentiation and 
proliferation. When we cultured freshly purified bone marrow stem cells for 15 minutes in the 
presence of VEGI, we were able to see an immediate dose-dependent decrease in the 
phosphorylation of Akt, which is known to be important for EPC homing and differentiation 
[99].  Therefore, the diminished Akt signaling may contribute to the inhibition of early EPC 
differentiation.  When we examined Erk and p38 phosphorylation in the same conditions, we 
found a significant activation of both these MAPKs by VEGI.  As Erk promotes cell proliferation 
and survival, activation of this kinase may provide the protective effect found on early stage 
undifferentiated EPCs.  Meanwhile, p38 has been shown to inhibit EPC numbers [101].  Thus 
p38 activation may be an additional factor in inhibiting early stage EPC differentiation.  These 
data suggest that the inhibitory effect of VEGI on the differentiation and apoptosis of early stage 
EPCs results from decreased Akt and increased Erk and p38 signaling.  
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In summary, this study demonstrates that VEGI has an inhibitory effect on the 
differentiation of BM-derived EPCs toward ECs.  Our findings indicate that VEGI negatively 
modulates BM-derived EPCs by down-regulating EC marker expression in early stage EPCs and 
inducing apoptosis in late stage EPCs.  In addition, VEGI inhibits the ability of BM-derived 
EPCs to adhere, migrate, and form capillary-like structures. Furthermore, we show that the 
inhibitory activity of VEGI is likely mediated by DR3 in late stage cultures and changes in cell 
signaling molecules in early stage cultures.  These findings support the view that VEGI plays a 
role in regulating postnatal vasculogenesis by modulating BM-derived EPC differentiation. 
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3.0  VEGI INHIBITS BM-DERIVED EPC SUPPORTED TUMOR 
VASCULOGENESIS 
 
3.1 ABSTRACT 
Bone marrow (BM)-derived endothelial progenitor cells (EPCs) have a critical role in tumor 
neovascularization. Vascular endothelial growth inhibitor (VEGI; TL1A) is a member of the 
TNF superfamily (TNFSF15). We have shown that recombinant VEGI suppresses tumor 
angiogenesis by specifically eliminating proliferating endothelial cells (ECs).  We report here 
that treatment of tumor bearing mice with recombinant VEGI leads to a significantly decreased 
population of BM-derived EPCs in the tumors. We transplanted whole bone marrow from green 
fluorescent protein (GFP) transgenic mice into C57BL/6 recipient mice, which were then 
inoculated with Lewis lung carcinoma (LLC) cells. Intraperitoneal injection of recombinant 
VEGI led to significant inhibition of tumor growth and decrease of vasculature density compared 
to vehicle-treated mice.  Tumor implantation yielded a decrease of BM-derived EPCs in the 
peripheral blood, while VEGI treatment resulted in an initial delay of such decrease.  Analysis of 
the whole bone marrow showed a decrease of Lin--c-Kit+-Sca-1+ hematopoietic stem cell (HSC) 
population in tumor bearing mice; however, VEGI treatment caused a significant increase of this 
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cell population.  In addition, the number of BM-derived EPC in VEGI-treated tumors was 
notably less than that in the vehicle-treated group, and most of the apoptotic cells in the VEGI-
treated tumors were of bone marrow origin.  These findings indicate that VEGI inhibits BM-
derived EPC mobilization and prevents their incorporation into LLC tumors by inducing 
apoptosis specifically of BM-derived cells, resulting in the inhibition of EPC-supported tumor 
vasculogenesis and tumor growth. 
3.2 INTRODUCTION 
Bone marrow (BM)-derived endothelial progenitor cells (EPCs) play a critical role in 
vasculogenesis, the de novo formation of new blood vessels which is essential for organ and 
tissue growth, and wound healing [11, 17, 18, 67, 82].  Abnormal neovascularization under 
disease conditions, such as that in cancer development, also involves postnatal vasculogenesis [4, 
30].  Early theories of tumor neovascularization revolved solely around angiogenesis being the 
source for the tumor’s vascular supply [22, 29].  New evidence shows that EPCs migrate from 
the bone marrow to the tumor site and differentiate into a new endothelium in the tumor bed, 
providing an alternative method of tumor neovascularization [19, 31, 68, 72, 81].  Contributions 
of EPCs to tumor neovasculature are evident from increased EPC markers in tumors of cancer 
patients [30, 32, 33].  It has also been shown that EPCs activate the “angiogenesis switch,” a 
critical step in the transition of an avascular, dormant tumor to a vascularized, rapidly growing 
tumor [34]. 
 Vascular endothelial growth inhibitor (VEGI; TNFSF15; TL1A) is a member of the 
tumor necrosis factor superfamily and an endogenous inhibitor of neovascularization [126].  
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VEGI is largely produced by vascular endothelial cells (ECs) of established blood vessels in a 
normal tissue, and is a specific inhibitor of EC proliferation, apparently playing a role in the 
modulation of vascular homeostasis.  More specifically, VEGI has the ability to enforce growth 
arrest of ECs in G0 and G1 phases of the cell cycle, while inducing apoptosis of proliferating 
EC, leading to inhibition of angiogenesis [138, 155].  While VEGI is expressed in the vascular 
EC of normal human adult tissues, it is absent or expressed at low levels in tumor vasculatures in 
breast cancer [134], prostate cancer [147], urothelial cancer [148], as well as during wound 
healing [143], supporting the view that VEGI is a negative regulator of neovascularization whose 
expression needs to be turned down prior to the initiation of physiological or pathological blood 
vessel growth. Consistently, recombinant VEGI has been shown to be a highly potent inhibitor of 
EC proliferation in tumors, resulting in specific elimination of ECs in a tumor vasculature and 
inhibition of tumor growth [127, 131, 137].    
 In this study, we examine whether VEGI can inhibit BM-derived EPC-supported 
vasculogenesis in a Lewis lung carcinoma (LLC) tumor model.  We found that systemically 
administered recombinant VEGI can inhibit the incorporation of BM-derived EPCs into LLC 
tumors and the differentiation of EPCs into ECs in these tumors.  These findings provide 
important insights into the mechanism of modulation of EPC-supported vasculogenesis by this 
unique cytokine and endogenous inhibitor of angiogenesis. 
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3.3 MATERIALS AND METHODS 
3.3.1 Antibodies and reagents 
Fluorochrome-conjugated anti-mouse Flk-1, CD133, c-Kit, and Sca-1 antibodies were from 
eBioscience (San Diego, CA).  EasySep Mouse Hematopoietic Progenitor Enrichment Cocktail 
for lineage selection was from Stem Cell Technologies (Vancouver, BC, Canada).  Anti-mouse 
CD31 antibody was from BD Biosciences (San Jose, CA).  Cy3 and Cy5 conjugated secondary 
antibodies were from Jackson ImmunoLabs (West Grove, PA).  Terminal Transferase, 
recombinant, kit for TUNEL staining was from Roche Applied Science (Indianapolis, IN).  
VEGI isoform VEGI-192 was prepared as described [131].  The endotoxin level in the VEGI 
preparation is 25 ng/mg. 
3.3.2 Cells 
Lewis lung carcinoma (LLC) cells were purchased from American Type Culture Collection 
(Manassas, VA).  Cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Lonza, 
Walkersville, MD) supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products, 
West Sacramento, CA). 
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3.3.3 Mice 
Eight week old female C57BL/6 mice (wild-type mice) and C57BL/6 EGFP10sb/J mice 
(transgenic mice that express GFP in all cell types) were purchased from the Jackson Laboratory 
(Bar Harbor, ME).  All procedures involving experimental animals were performed in 
accordance with protocols approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. 
3.3.4 Bone marrow transplantation and engraftment analysis 
Whole bone marrow from C57BL/6 EGFP10sb/J donor mice was harvested by flushing the 
femurs and tibias of adult animals.  C57BL/6J recipient mice were lethally irradiated with 9 Gray 
of a cobalt source.  After lethal irradiation, the recipient mice received 5 x 106 whole bone 
marrow cells via lateral tail vein injection.  One month after bone marrow transplant (BMT), 
blood was obtained from the tail veins and engraftment was verified by flow cytometric analysis 
to confirm stable and complete chimerism, as indicated by >85%  of GFP+ cells in peripheral 
blood.   
3.3.5 Tumor inoculation and VEGI administration 
One month after BMT, the chimeric mice were injected subcutaneously with 5 x 106 LLC 
suspended in phosphate-buffered saline (PBS, Lonza).  Tumors were allowed to grow for 4 days 
and measured in a blinded manner with a dial caliper.  The tumor volumes were determined 
using the formula, volume = width x width x length x 0.52.  The experimental animals were then 
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randomized and divided into two groups on day 4.  The treatment group received one daily i.p. 
injection of VEGI while the control group received comparable injections of the vehicle (on days 
4, 5 and 6 for a total of three treatments).  The experimental animals were sacrificed on day 7.  
Tumor tissues, peripheral blood and bone marrow were collected for pathologic analysis. 
3.3.6 Flow cytometry 
Cells were harvested (for peripheral blood analysis samples, 100 µl of blood was collected from 
the tail vein of each experimental mouse, and for bone marrow samples, whole bone marrow was 
collected from femurs and tibia via bone marrow flush) and lysed with ACK cell lysis buffer 
(Lonza).  Cells were then washed with 2 mL of fluorescence-activated cell sorter (FACS) buffer 
(1% bovine serum albumin and 0.05% sodium azide in PBS).  The cells were collected by 
centrifugation, resuspended in 100 µl of FACS buffer containing 1 µg of the indicated antibody, 
dispensed in a minimum of 1 x 105 cells/sample, gently mixed, and incubated at room 
temperature for 15 minutes.  The cells were washed with FACS buffer, centrifuged, resuspended 
in 0.5 mL PBS and analyzed within 1 hour.  Coulter FACS equipment and EXPO analysis 
software (Beckman Coulter, Fullerton, CA) were used.   
3.3.7 Immunohistochemistry 
Tumors were fixed with 2% paraformaldehyde in PBS at room temperature for 2 hours, then 
cyroprotected by transferring to a 30% sucrose solution overnight at 4°C.   Samples were flash 
frozen in liquid nitrogen cooled 2-Methylbutane for 30 seconds, then immersed in liquid nitrogen 
for an additional 10 second and stored at -80°C until cryostat sectioning. Tumor sections (8 µm 
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thickness) were immunostained by first being blocked for non-specific antibody binding with 2% 
BSA, followed by incubation with primary antibodies for 1 hour at room temperature.  After 5 
washes with PBS, sections were incubated with secondary antibodies for 1 hour at room 
temperature and then washed again with PBS.  After nuclei staining with DAPI, sections were 
mounted.  Immunostained sections from peripheral and central regions of each tumor were 
imaged using a 60x oil objective on a Fluo-view 1000 confocal microscope (Olympus, Center 
Valley, PA).  A minimum of 10 fields/section and 10 sections/tumor sample were analyzed. 
3.3.8 Detection of apoptotic cells 
Cryosections were washed 3x with PBS and incubated with TUNEL mixture at 37°C for 30 
minutes, washed with PBS, then streptavidin secondary antibody was added for 30 minutes at 
room temperature.  DAPI was used to stain for the cell nucleus and slides were mounted before 
imaging. 
3.3.9 Statistical analysis 
At least three repeat experiments (n=3-5 per group) were performed yielding similar results.  
Results shown are of 1 experiment.  Student’s t-test for independent samples was used to 
compare data between experimental groups.  All data presented as the mean ± SE; P<0.05 was 
considered statistically significant and is indicated with an asterisk. 
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3.4 RESULTS 
3.4.1 VEGI inhibits tumor growth and vascularization 
Female mice (C57BL/6) with transplanted bone marrow from green fluorescent protein (GFP) 
transgenic mice were inoculated on day 0 with LLC cells subcutaneously (5x106 cells per 
injection).  On day 4 following the initial inoculation of LLC cells, the experimental animals 
were treated with recombinant VEGI by intraperitoneal injection (I.P.) (5mg/kg), with repeats on 
day 5 and day 6.  The control group was treated with vehicle. The size of the tumors was 
measured daily. We found a significant inhibition of tumor growth rate in the VEGI-treated 
group compared to that in the control group (Figure 22).  On day 7, the average tumor volume of 
the VEGI-treated group was 62% of that of the control group. 
 
 
 
 
 
 
 
 
 
Figure 23.  VEGI inhibits the growth of LLC tumors.   
Average tumor size in mice treated with either vehicle (Control, n=6) or VEGI (n=6) given by 
intraperitoneal injection.   
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The tumors were harvested on day 7.  Cryostat sections of the tumor samples were analyzed for 
vascular density using immunohistochemical staining for CD31, a marker of ECs.  The intensity 
of CD31 immunostaining was scored on a scale of 1-4 (Figure 23A).  We found that the mean 
intensity score was significantly lower in the VEGI-treated tumors than in vehicle-treated tumors 
(2.06 ± 0.07 vs 3.05 ± 0.06, respectively), indicating less vascular formation (Figure 23B).  
These results demonstrate that VEGI treatment leads to retarded growth of the LLC tumors and 
decreased vascularization in the tumors. 
 
 
    A 
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Figure 24.  VEGI treatment inhibits tumor vascularization. 
A.  Representative images of tumor samples immunostained for CD31 and scored on a scale of 1-4, with 
4 being the most.  Red, CD31.  B.  Box plot showing average intensities of CD31 scored on Day 7 LLC 
tumor samples. 
 
3.4.2 VEGI impact on peripheral blood EPC and bone marrow hematopoiesis 
To determine whether VEGI has any impact on BM-derived EPCs in the periphery blood as well 
as in the bone marrow, we first analyzed the number of circulating EPC in the peripheral blood 
of tumor bearing mice treated with VEGI or vehicle.  Blood was collected immediately prior to 
cancer cell inoculation and analyzed by using flow cytometry to identify BM-derived GFP+ cells 
that were also positive for both Flk-1 (vascular endothelial growth factor receptor 2), an EC 
marker, and CD133 (Prominin-1), an indicator of stem cells.  Blood was collected again four 
days after tumor inoculation, prior to VEGI treatments, in order to determine any change in the 
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number of BM-derived EPCs because of the tumor burden.  Comparing to the baseline of day 0, 
we found an about five-fold decrease in the number of GFP+-Flk-1+-CD133+ cells four days after 
tumor inoculation (Figure 24), suggesting active recruitment of periphery blood EPC into the 
tumor.  We also analyzed blood collected on day 5, 6, and 7 for changes in BM-derived EPC 
resulting from the daily VEGI treatments.  Interestingly, 24 hours after the initial VEGI 
treatment, we found a 64% increase in the number of GFP+-Flk-1+-CD133+ cells compared to the 
vehicle-treated group.  However, this difference between the VEGI-treated group and vehicle-
treated group disappeared on the following days (Figure 24).  These findings suggest that VEGI-
treatment results in an inhibition of the recruitment of the blood-borne EPC by the tumor, albeit 
transient under the experimental conditions.  
 
 
 
 
 
 
 
 
 
 
Figure 25.  Effect of VEGI treatment on peripheral blood EPCs. 
Fold change of circulating EPC (GFP+-Flk-1+-CD133+).  Blood was collected via tail vein on day 0 prior 
to tumor inoculation and on days 4, 5, and 6 prior to VEGI treatment (n=3 per group).  Day 7 blood 
samples collected 24 hours after the last treatment. 
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We also looked for changes in the hematopoietic stem cell (HSC) population (Lin--c-
Kit+-Sca-1+) in the bone marrow of the VEGI- or vehicle-treated groups by flow cytometry, and 
compared the results with those of the bone marrow of normal non-tumor bearing mice.  We 
found that there was an about 80% increase in the population of HSC in the bone marrow 
without tumor burdens because of VEGI treatment (Figure 25).  By solely having a tumor 
burden, the population of purified HSC in the bone marrow exhibited a 53% decrease (Figure 
25), possibly because of their mobilization induced by vascular trauma such that occurs in tumor 
neovascularization. VEGI treatment of the tumor bearing group caused the percentage of Lin--c-
Kit+-Sca-1+ HSC in the bone marrow to increase to a level similar to those found with VEGI-
treated, non-tumor bearing mice (Figure 25). These findings suggest that VEGI treatment has an 
inhibitory effect on the mobilization of BM-derived EPCs into the circulation. 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Effect of VEGI treatment on bone marrow HSCs.  
Percentages of HSCs (Lin--c-Kit+-Sca-1+) in whole bone marrow on Day 7.  Samples analyzed by using 
flow cytometry. 
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3.4.3 VEGI inhibits BM-derived EPC incorporation into LLC tumors 
In order to investigate the impact of VEGI treatment on the incorporation of BM derived-EPCs 
into the LLC tumors, tumor sections were immunostained for EC marker CD31. GFP and CD31 
double positive cells were identified by confocal microscopy.  In the tumor samples of the 
vehicle-treated animals, we were able to detect areas highly populated with GFP+-CD31+ cells 
(Figure 26A).  In contrast, the tumor samples from the VEGI-treated group consisted of 
significantly fewer GFP+-CD31+ cells (Figure 26A).  By counting the number of GFP+-CD31+ 
cells in the tumor sections (Figure 26B), we found that the number of double positive cells in the 
tumors of VEGI-treated animals was 56% of that in the control group (Figure 26C).  This finding 
indicates that VEGI treatment resulted in a lowered number of EC originating from BM-derived 
EPCs in the tumors compared with that of vehicle-treated tumors. 
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Figure 27.  VEGI inhibits EPC incorporation into LLC tumors.   
A. Representative confocal images of immunostaining for BM-derived EPCs in LLC tumors collected on 
Day 7 following cancer cell inoculation and 24-hours after the last of three daily VEGI treatments. Green, 
GFP; Red, CD31; Blue, cell nuclei; Scale bar, 20 µm. B. High magnification of the boxed area shown in 
Panel A. Arrows indicate GFP+-CD31+ cells.  C.  Quantification of the number of GFP+-CD31+ cells from 
randomly selected fields on each tumor section; a minimum of 10 fields per tumor sample were counted 
from each animal (n=4 per group). 
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3.4.4 VEGI induces apoptosis of BM-derived cells 
To investigate the cause of the diminishing population of BM-derived ECs in the tumors of 
VEGI-treated animals, we used TUNEL staining to determine the extent of the apoptosis of BM-
derived cells (Figure 27A).  More specifically, we determined overall apoptosis in the tumors as 
well as apoptosis of GFP+ cells derived from the bone marrow (Figure 27B).  In the VEGI-
treated tumors, the total number of apoptotic cells was more than two-times of that in the 
controls.  Remarkably, the number of apoptotic GFP+ cells in the VEGI-treated group was more 
than three-times of that in the controls (Figure 27C).  Additionally, while about 40% of all 
apoptotic cells in the control group were GFP+, nearly 70% of the apoptotic cells in the VEGI-
treated group were GFP+ (Figure 27C).  These findings suggest that VEGI treatment gives rise to 
apoptosis of BM-derived cells that have been recruited into the tumors. 
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Figure 28.  Induction of apoptosis of BM-derived cells by VEGI-treatment.   
A. Representative confocal images of Day 7 LLC tumor samples analyzed for apoptosis. Green, GFP; 
Red, CD31; Magenta, TUNEL; Blue, cell nuclei; Scale bar, 20 µm.  B. High magnification of the boxed 
area shown in Panel A. TUNEL positive cells (arrow heads) and GFP+-TUNEL+ cells (arrows) are 
indicated.  C.  Average number of TUNEL positive cells per field in vehicle-treated control or VEGI-
treated tumors.  A minimum of 10 fields per tumor sample were counted from each animal (n=4 per 
group). 
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3.5 CONCLUSIONS 
Tumor vasculature arises through two processes: angiogenesis supported by ECs from existing 
blood vessels [4], and vasculogenesis supported by an alternative source of ECs, known as BM-
derived EPCs [18, 82].  VEGI inhibits angiogenesis by specifically inhibiting EC proliferation 
and inducing apoptosis of proliferating ECs, resulting in suppression of tumor growth [131, 155]. 
To demonstrate in animal tumor models whether VEGI, an endogenous cytokine, can inhibit 
BM-derived EPC-supported vasculogenesis and thereby suppress this alternate method of 
neovascularization is important to the understanding of the mechanism of tumor 
neovascularization.  The study may also yield pivotal insights into potential anticancer 
therapeutic approaches.  The data we show here indicate that VEGI is able to inhibit EPC-
supported vasculogenesis in tumors. 
The function of EPCs in supporting tumor vasculogenesis has been debated extensively 
in previous studies.  In some reports, the role of EPCs in tumor vascularization has been shown 
to be highly significant, not only contributing between 50-100% of the tumor vasculature, but 
also inducing neovasculogenesis [33, 34, 107].  BM-derived EPCs are shown to be critical for 
activating the angiogenic switch, which induces the vascularization of a tumor, as blocking EPCs 
not only inhibits angiogenesis and impairs tumor metastases, but also leads to prolonged survival 
of tumor bearing mice [34].  Other studies have shown, however, that EPC contribution is 
negligible, compromising no more than 5% of the ECs in the tumor [119, 120, 167, 168].  
Apparently an important factor attributing to the discrepancies is the timeframe of when EPCs 
incorporation into the tumor vasculature was analyzed.  It has been reported that BM-derived 
EPCs participate in early tumor vascularization, forming BM-derived vessels, before their 
incorporation is diluted by peripheral vessels resulting from angiogenesis [123].  Therefore, we 
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examined the contribution of EPCs to tumor vasculogenesis within the timeframe when 
subcutaneously implanted LLC form palpable tumors, approximately within a few days of cancer 
inoculation.  Treatment of the tumor bearing mice with VEGI resulted in a marked retardation of 
tumor growth, accompanied by a decrease in vascular density in the tumors.  These data are 
consistent with the view that VEGI is able to negatively regulate EPC-supported nascent 
neovascularization during the early formation of LLC tumors.  
EPCs are thought to migrate out of the bone marrow into the periphery and home to a site 
of vascular trauma, such as occurs during tumor vasculogenesis [31, 68, 81].  We examined the 
peripheral blood of the experimental mice before and after tumor cell inoculation as well as after 
VEGI treatment to determine if there is any difference in the circulating BM-derived EPC 
population.  Previous studies have indicated that EPCs are mobilized from the BM into the 
circulation, then incorporated into the vascular bed within 48 hours after tumor inoculation in 
animal models [18, 33, 81].  We determined the baseline amount of circulating BM-derived 
EPCs prior to tumor inoculation, and found that four days of possessing a tumor burden 
significantly deprived the amount of BM-derived EPCs in the blood.   It is likely that the BM-
derived EPC population in the blood of the experimental animals diminishes because these cells 
are incorporated into the tumor.  We then treated the tumor bearing mice with VEGI.  While no 
further change was seen in the amount of circulating BM-derived EPCs in the vehicle-treated 
control group, there was an increase of circulating BM-derived EPCs in the blood of VEGI-
treated mice compared to the control group one day after initial VEGI treatment.  Interestingly, 
however, the levels of circulating BM-derived EPCs in the VEGI treated group declined to the 
same level seen for the vehicle-treated control group within the next 24 hours.  It is plausible that 
the temporary increase in BM-derived EPC arises from VEGI inhibiting the ability of EPCs to 
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adhere to a site of vascular trauma, causing a transient accumulation of BM-derived EPCs in the 
blood.  
The subsequent decline of circulating EPCs in VEGI-treated, tumor bearing animals may 
be explained in terms of the inhibition of cancer cell-induced HSC mobilization from the bone 
marrow. We analyzed the whole bone marrow of the experimental mice for the percentage of 
Lin--c-Kit+-Sca-1+ HSC, which share a common lineage with EPCs [60, 169], after three days of 
VEGI treatment.  We compared the percentage of the HSCs in the tumor bearing mice to non-
tumor bearing mice and found that the tumor burden leads to a marked decrease of the 
percentage of these cells, while VEGI treatment caused  the number of Lin--c-Kit+-Sca-1+ cells in 
the bone marrow to increase by about three-fold.  A relatively larger percentage of HSCs within 
the bone marrow, but a lower percentage of BM-derived EPCs in the circulation, suggests that 
VEGI inhibits tumor-induced HSC mobilization in the bone marrow.  Alternatively, the increase 
of the percentage of Lin--c-Kit+-Sca-1+ cells in the bone marrow by VEGI treatment suggests 
that VEGI promotes HSC production. This possibility will be investigated in future studies. 
The significant decrease in the number of EPCs incorporated into the tumor site of VEGI-
treated mice, compared to that in vehicle-treated mice, may be because of not only VEGI 
inhibition of the mobilization of HSCs in the bone marrow and inhibition of EPC adherence, but 
also the possibility of VEGI inducing apoptosis of BM-derived EPCs.  Given the unique ability 
of VEGI to induce apoptosis of only proliferating EC, we utilized CD31, a widely accepted 
marker of EC lineage, to visualize BM-derived EPCs and their response to VEGI.  We found that 
VEGI treatment not only caused an increase in the number of overall apoptotic cells in the 
tumor, but specifically induced the apoptosis of cells deriving from the bone marrow, giving rise 
to a diminished BM-derived EPC population in the tumor. 
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In summary, this study illustrates the role of VEGI as an inhibitor of BM-derived EPC 
incorporation and differentiation in LLC tumors.  Our findings indicate that VEGI inhibits BM-
derived EPC-supported tumor vasculogenesis, ultimately inhibiting tumor growth.  In addition, 
we show that tumor burdens mobilize EPCs from the bone marrow and recruit circulating EPCs, 
and that VEGI suppresses this process.  Further, we show that VEGI directly inhibits BM-
derived EPC-supported tumor vasculogenesis by specifically inducing apoptosis in BM-derived 
cells in the tumors.  These findings are consistent with the view that VEGI plays a critical role in 
the modulation of EPC-supported postnatal vasculogenesis. 
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4.0  DISCUSSION 
The emphasis of these studies was to investigate the effect of VEGI activity on BM-derived 
EPCs to gain a better understanding of the potential therapeutic value of VEGI for inhibiting 
tumor vasculogenesis.  In our effort, we utilized recombinant VEGI to treat cultures of bone 
marrow stem cells stimulated to differentiate into ECs in an attempt to deduce whether VEGI is 
able to inhibit their proliferation in vitro.  We also determined whether VEGI could specifically 
inhbit BM-derived EPC supported vasculogenesis in a tumor model of LLC. Furthermore, we 
collected preliminary evidence on the mechanism of action by VEGI in these experiments.   Our 
results support the hypothesis that VEGI is a biological inhibitor capable of inhibiting tumor 
vasculogenesis. 
4.1 MODULATION OF BM-DERIVED EPC IN VITRO 
4.1.1 VEGI inhibits differentiation of BM-derived EPC 
The discovery of progenitor cells of endothelial lineage, EPCs, which can differentiate into 
mature ECs has led to many studies on the role of these cells in vascularization [11].  It has been 
widely reported that EPCs derive from the bone marrow and contribute to neovascularization by 
homing to a site of vascular injury where it aggregates, proliferates, and differentiates to form an 
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entirely new vessel.  This process of vasculogenesis has been determined to be important to 
normal physiological vascular repair as well as in pathological uncontrolled blood vessel 
formation [18].  It has been shown that there are multiple factors that contribute to the 
upregulation of BM-derived EPCs, such as VEGF and FGF-2 [81, 162].  However, there are few 
reports dedicated to the understanding of negative regulators of BM-derived EPCs.   
One of the more prominent roles of VEGI is its regulation of EC proliferation by 
targeting those cells for apoptosis [155].  Because VEGI has a specific role in attenuating 
angiogenesis, we wanted to determine if VEGI was also able to exhibit anti-proliferative and 
pro-apoptotic actions on EPCs.  To delineate VEGI’s role in regulating BM-derived EPCs, we 
initially had to isolate and characterize EPCs.  To date, there have been multiple methods 
described for EPC isolation, but no distinct consensus on one method [48, 151].  The 
characterization of EPCs have been further hindered based on the fact that EPCs and HSCs, both 
derived from hemangioblasts [66], share many of the same cell surface markers, the primary 
method of determining EPCs from more primitive HSCs.  In our lab, we utilized Sca-1+ cell 
selection to isolate early stage EPCs directly from mouse bone marrow, because Sca-1 is a 
widely recognized marker for adult murine HSCs and typically utilized by other investigators to 
isolate EPCs from mouse bone marrow. We found that a high density of Sca-1+ cells and low 
serum concentration in the culture media is essential for BM-derived EPC survival and 
differentiation. This observation is in accordance with previous reports [170, 171].   
Isolated cells were stimulated in culture media containing essential EC growth factors.  
We found that during the initial days of culture, freshly isolated cells were unable to adhere to 
the culture plates.  This may be due to the fact that these cells express only stem cell markers and 
are considered to be the early population of EPC.  These early stage EPCs slowly differentiate 
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toward ECs, which was immediately visible in their change in morphology.  Concurrently, it was 
seen that these later stage EPCs begin to express surface markers indicative of committed EC 
lineage while expression of their stemness was decreased.  In our determination of BM-derived 
EPCs, we examined a battery of markers that have been repeatedly distinguished by many 
groups as identifying markers for EPC. 
Overall, we determined that a mixture of both stem cell markers (Sca-1 and CD133) and 
EC markers (Flk-1, Tie-2, and E-selectin) allowed for characterization of BM-derived EPCs over 
a course of a two-week culture.  We found that VEGI inhibits early stage EPC progress into 
differentiated EPCs by examining these same markers. Unlike EPCs in the control group, cells 
cultured in the presence of VEGI have up to a 50% lowered expression of only endothelial 
markers (Flk-1, Tie-1, E-selectin, and VE-cadherin).   However, there was no difference in the 
expression level of Sca-1 and CD133, which in both control and VEGI treated groups, was 
lowered after 10 days of culture.  These data suggest that VEGI could largely inhibit, but not 
completely prevent, EPC differentiation from bone marrow cells.  
4.1.2 VEGI inhibits BM-derived EPC functionality 
We state that VEGI is able to inhibit BM-derived EPC differentiation based on decreased levels 
of surface markers, but we also tested the functionality of the cells to confirm this finding.  EPCs 
are known to have migratory and adhesive functionality required for their transport to sites 
requiring neovascularization.  In our culture system, VEGI treatment significantly diminished the 
ability of EPC to adhere to extracellular matrix proteins fibronectin and vitronectin.  Besides 
limiting EPCs adhesion to culture coated plates, VEGI also downregulated EPC ability to 
migrate across both an open space and a porous barrier. Utilizing the wound healing assay to 
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determine the ability of cells to move into an open space on a flat surface in a unit of time, 
control cells exhibited a mobility that is nearly two times faster than VEGI-treated cells. 
However, when measured in a transwell assay to determine the ability of the cells to pass 
through a porous barrier, the speed of the untreated cells is only about 25% faster than VEGI-
treated cells. This discrepancy likely resulted from the larger size of the untreated cells, which 
were able to differentiate and elongate, ultimately hindering their mobility through the porous 
filters in the latter assay. The different migration time (48 hours vs. 8 hours) may also cause the 
difference of the inhibition rate. Moreover, the ability of EPCs to form capillary-like tubes on 
extracellular matrix proteins decreases substantially as a result of VEGI treatment. These 
findings strongly suggest that VEGI inhibits early stage EPC differentiation toward ECs and 
preventing their functional properties. 
4.2 MECHANISMS OF VEGI ACTION IN BM-DERIVED EPC INHIBITION 
The mechanism involved in VEGI inhibition of BM-derived EPC differentiation and function is 
unknown.  However it is presumed that VEGI is able to regulate factors involved in EPC growth 
signaling.  Additionally, it is thought that VEGI may downregulate proteins necessary for EPC 
mobilization.  The importance of integrin receptors α5β1 and αvβ3 are known for EC migration, 
in which ECs interact with the extracellular matrix via these proteins [164, 165].  Since VEGI 
treated cells are unable to adhere to fibronectin and vitronectin in culture conditions, we looked 
for the expression of integrins on these cells and found a decreased expression.  It appears as 
though VEGI, by inhibiting the production of these integrins on BM-derived EPC, leads to the 
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decreased migration and adhesion seen in vivo.  This could be one part of the mechanism by 
which VEGI negatively modulates EPC differentiation. 
VEGI treatment inhibits early stage EPCs adhesion and causes the cells to remain largely 
undifferentiated and suspended in culture.  In control cultures without VEGI, many of the cells 
were able to adhere, and those cells which did not adhere undergo apoptosis.  We were able to 
determine that VEGI decreased the rate of apoptosis in the suspended cells, giving rise to the 
idea that VEGI may have a protective effect on early stage EPC.  On the other hand, VEGI 
treatment led to increased apoptosis of adherent cells while no apoptosis was detected in 
untreated cells.  These results suggest that differentiated and undifferentiated EPCs respond to 
VEGI activity in a very different manner that is yet to be determined. 
One possible variable in the different apoptotic response by differentiated vs. 
undifferentiated EPCs may be due to the expression of DR3 on these cells.  DR3 has been 
described as the receptor for VEGI and mediates the apoptotic pathway response [133].    We 
found that DR3 is not detected in BM-derived EPCs until approximately 1 week in culture, 
consistent with when cells begin to undergo apoptosis in response to VEGI treatment.  DR3 
expression increases markedly in differentiated EPCs after 10 days in culture and accordingly, 
apoptosis rates increase profoundly after 11 days of culture. An activated caspase cascade in 
VEGI-treated EPCs is observed only after the expression of DR3 and can be reversed using 
DR3-neutralizing antibodies.  These data indicate that DR3 is likely the mechanism by which 
VEGI can exert its inhibitory effect on BM-derived EPCs.   
Activation of protein kinases have been reported to be essential for VEGI induced 
apoptosis and inhibition of ECs.  It appears that these proteins are also involved in the inhibition 
of EPCs by VEGI, but not via pro-apoptosis.  As the early EPCs have yet to express DR3, it is 
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unknown how VEGI is signaling to these cells.  However, it is apparent the VEGI does interact 
with early EPC to inhibit differentiation.  In BM-derived EPC cultures, treatment with VEGI 
leads to an immediate decline of Akt phosphorylation. Akt signaling pathway plays an important 
regulatory role in the differentiation of EPCs [99], therefore the inhibition of Akt by VEGI may 
contribute to the reason early EPCs are retained in an undifferentiated state.  Not only does 
VEGI inhibit differentiation of cells in culture, but it has been shown that VEGI actually 
supports undifferentiated cell survival, protecting it from undergoing apoptosis, which was 
unexpected.  This mechanism of VEGI may relate to Erk and p38, which are both activated by 
VEGI treatment in early EPCs. Activation of the Erk signaling pathway is essential for cell 
proliferation and survival, presenting a plausible mechanism underlying the protection of early-
stage EPCs and increased cell numbers compared to untreated controls.  Activation of p38 has 
been shown to inhibit EPC proliferation [101], perhaps contributing to the inhibitory effect of 
VEGI on EPC differentiation. 
4.3 MODULATION OF BM-DERIVED EPC IN VIVO  
4.3.1 BM-derived EPC-supported vasculogenesis 
It has been well established that VEGI plays a role in inhibiting the proliferation of mature ECs 
[131, 155], therefore it is highly likely that it can exert a similar effect on the precursors of ECs.  
These precursors derived from the bone marrow are termed BM-derived EPCs.  EPCs have been 
postulated to play a main role in triggering the onset of vascularization in tumors, which results 
in uncontrolled growth of the tumor [34].  The tumor vasculature has been shown to be a vital for 
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the survival and growth of a tumor, providing necessary nutrients and oxygen to hypoxic regions 
and forming a critical vascular network allowing for the metastasis of tumor cells to secondary 
sites [21, 27].  As metastasis will lead to the eventual death of the tumor host, it is imperative to 
prevent or eliminate this vascular pathway, which can not only halt the progression of the 
disease, but perhaps abolish the primary tumor as well.   
The contribution of EPCs to tumor vasculogenesis has been debated extensively in 
previous studies.  While some groups have reported that the role of EPCs in tumor 
vascularization is highly significant [18, 30, 33, 34], other have stated that EPC contribution is 
negligible [119, 120, 167, 168].  It has been reported that the different methods of analyzing EPC 
incorporation into a tumor and the tumor model itself may be an important factor attributing to 
these discrepancies.   One model that has been used repeatedly and has been shown to involve 
EPC-supported tumor vasculogenesis is the LLC model [34].  In our hand, we found that EPC do 
incorporate into a tumor bed, albeit at a low percentage that is consistent with other groups 
utilizing a LLC tumor model [34].  It was seen that EPC constitute a small percentage of the 
overall circulating blood and low numbers were found at the tumor site on day 7.  Our decision 
to utilize such an early tumor mass was based on recent reports that BM-derived EPC participate 
in early tumor vascularization before their incorporation is diluted by peripheral vessels [123].   
4.3.2 VEGI inhibits BM-derived EPC in circulation 
BM-derived EPCs are shown to be the critical factor inducing the vascularization of a tumor.  It 
has been shown that blocking EPCs not only inhibits angiogenesis and impairs tumor metastases, 
but also leads to prolonged survival of tumor bearing mice [34].  Endogenous inhibitors of 
angiogenesis play a pivotal role in controlling the angiogenic balance but they become 
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downregulated during tumor progression, allowing for uncontrolled vascular growth [172]. Re-
introduction of endogenous inhibitors in the tumor microenvironment may help to restore the 
angiogenic balance. With this in mind, we tested the ability of VEGI to block EPC-supported 
vasculogenesis.  First, it was shown that treatment of the tumor bearing mice with VEGI resulted 
in a marked retardation of tumor growth that was accompanied by a decrease in vascular density 
in the tumors, suggesting VEGI negatively regulates neovascularization during the early 
formation of LLC tumors.  
We examined the peripheral blood of experimental mice for circulating levels of BM-
derived EPCs in order to determine whether the tumor growth inhibition and decreased 
vasculature caused by VEGI treatment was due to EPC-supported vasculogenesis and not solely 
VEGI’s inhibitory activity on ECs and angiogenesis.  It was determined that circulating BM-
derived EPC populations drastically decreased 4 days after tumor inoculation, consistent with 
previous studies that have indicated EPCs incorporate into tumor vasculature within the first 2 
days of tumor burden in mice [18, 33, 81].  It is likely that the decreased population of BM-
derived EPCs found in the blood of the experimental animals diminished because these cells had 
already incorporated into the tumor.  Interestingly, there was an increase of circulating BM-
derived EPCs in the blood of VEGI-treated mice compared to the control group after initial 
VEGI treatment.  However, the increase was temporary and BM-derived EPC populations in the 
VEGI-treated group quickly declined to similar amounts seen for the vehicle-treated control 
group.  The temporary increase in BM-derived EPCs is hypothesized to be due to the inhibitory 
activity of VEGI on the ability of EPCs to adhere to a site of vascular trauma, causing a transient 
accumulation of BM-derived EPCs in the blood. This theory is supported our in vitro findings 
that EPCs in the presence of VEGI are unable to attach to culture plates coated with extracellular 
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matrix proteins and that the expression of integrin-α5 or -αV was substantially down-regulated by 
VEGI. Additionally, it is thought that after inhibiting EPC adhesion, VEGI then induces 
apoptosis of these cells, leading the ensuing population decline of BM-derived EPCs in the 
circulation.  A future study of the apoptosis rates of EPCs in blood after VEGI treatment can be 
of value in further exploring this possibility.  
Another possibility for the decline of EPCs in blood after treatment by VEGI may be due 
to the inhibition of HSC mobilization from the bone marrow.  It has been shown that EPCs and 
HSCs mobilize from the blood together [173].  We found an accumulation of HSCs in the bone 
marrow of VEGI-treated mice, regardless of tumor bearance, and it was seen that the percentage 
of HSCs actually increased to levels almost double that of normal controls.  This view is 
consistent with our in vitro data indicating that the ability of EPCs to migrate markedly declines 
after VEGI treatment.  Furthermore, the increase of the percentage of Lin--c-Kit+-Sca-1+ cells in 
the bone marrow by VEGI treatment suggests that VEGI not only inhibits the mobilization of 
HSCs from bone marrow into the periphery, but that VEGI may promote HSC production. This 
thought is in line with our data showing VEGI activates cell growth signals in early EPCs 
derived from Sca-1+ cells.  However, future studies on the whole bone marrow will be performed 
to further evaluate this possibility. 
4.3.3 VEGI inhibits BM-derived EPC in tumors 
BM-derived EPCs are low in their frequency, which makes it difficult to stain for their 
multiple markers while allowing for visualization of their co-localization.  Given the unique 
ability of VEGI to induce apoptosis of only proliferating EC [155], we therefore utilized CD31, a
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widely accepted marker of EC lineage, to visualize BM-derived EPCs and their response to 
VEGI.  It is important to note that CD31 is not solely found on ECs, but on other cells such as 
myeloid cells.  However, in conjunction with GFP, we were able to determine which CD31 cells 
derived from the bone marrow, a good indicator of BM-derived EPC.  A significant decrease in 
the number of EPCs incorporated into the LLC tumor site of VEGI-treated mice was observed.  
This phenomenon may occur in part to the inhibition of HSC mobilization from the bone marrow 
and the inhibition of circulating EPC adherence, as previously stated.   
The decrease in EPC incorporation may also be due to an apoptotic effect.  We 
determined the possibility of VEGI induced apoptosis of BM-derived EPCs, which is likely 
when taking into account the apoptosis of BM-derived cells seen in our VEGI-treated cultures.  
We found that VEGI treatment not only caused an increase in the number of overall apoptotic 
cells in the tumor, but specifically induced the apoptosis of cells deriving from the bone marrow, 
giving rise to a diminished BM-derived EPC population in the tumor.  Subsequent studies on 
tumor cell suspensions analyzed by flow cytometry could help confirm the decline of BM-
derived EPC as well as the increase in apoptosis. 
4.4 CONCLUDING REMARKS 
We focused on characterizing the inhibitory action of VEGI on BM-derived EPCs. We have 
shown that VEGI treatment of BM-derived cells in culture prevents their differentiation towards 
an EC lineage by suppressing EC-specific gene expression in early stage EPCs and inducing 
apoptosis of late stage EPCs.  Moreover, we have demonstrated that VEGI treatment in a LLC
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tumor model diminished BM-derived EPC incorporation into the tumors, hindering BM-derived 
EPC-supported tumor vasculogenesis and ultimately inhibiting tumor growth.  Together, these 
studies support our hypothesis that VEGI is a biologically significant inhibitor of tumor 
vasculogenesis and have resulted in a better understanding of VEGI and its potential impact for 
cancer therapy. 
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